<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86931</article-id><article-id pub-id-type="doi">10.7554/eLife.86931</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.86931.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The <italic>Mycobacterium ulcerans</italic> toxin mycolactone causes destructive Sec61-dependent loss of the endothelial glycocalyx and vessel basement membrane to drive skin necrosis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hsieh</surname><given-names>Louise Tzung-Harn</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9499-889X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hall</surname><given-names>Belinda S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3753-1978</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Newcombe</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mendum</surname><given-names>Tom A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Varela</surname><given-names>Sonia Santana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Umrania</surname><given-names>Yagnesh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Deery</surname><given-names>Michael J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Wei Q</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Diaz-Delgado</surname><given-names>Josué</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Salguero</surname><given-names>Francisco J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Simmonds</surname><given-names>Rachel E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4843-8266</contrib-id><email>rachel.simmonds@surrey.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ks66431</institution-id><institution>Discipline of Microbes, Infection &amp; Immunity, School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey</institution></institution-wrap><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>Cambridge Centre for Proteomics, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00k6tx165</institution-id><institution>Department of Chemistry, Ball State University</institution></institution-wrap><addr-line><named-content content-type="city">Muncie</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01f5ytq51</institution-id><institution>Texas A&amp;M Veterinary Medical Diagnostic Laboratory</institution></institution-wrap><addr-line><named-content content-type="city">College Station</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/018h10037</institution-id><institution>United Kingdom Health Security Agency, UKHSA-Porton Down</institution></institution-wrap><addr-line><named-content content-type="city">Salisbury</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Henrion</surname><given-names>Daniel</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04yrqp957</institution-id><institution>University of Angers</institution></institution-wrap><country>France</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01swzsf04</institution-id><institution>University of Geneva</institution></institution-wrap><country>Switzerland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>02</month><year>2025</year></pub-date><volume>12</volume><elocation-id>RP86931</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-02-21"><day>21</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-02-21"><day>21</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.21.529382"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-05-15"><day>15</day><month>05</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.86931.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-11"><day>11</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.86931.2"/></event></pub-history><permissions><copyright-statement>© 2023, Hsieh, Hall et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Hsieh, Hall et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86931-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-86931-figures-v1.pdf"/><abstract><p>The drivers of tissue necrosis in <italic>Mycobacterium ulcerans</italic> infection (Buruli ulcer disease) have historically been ascribed solely to the directly cytotoxic action of the diffusible exotoxin, mycolactone. However, its role in the clinically evident vascular component of disease aetiology remains poorly explained. We have now dissected mycolactone’s effects on human primary vascular endothelial cells in vitro. We show that mycolactone-induced changes in endothelial morphology, adhesion, migration, and permeability are dependent on its action at the Sec61 translocon. Unbiased quantitative proteomics identified a profound effect on proteoglycans, driven by rapid loss of type II transmembrane proteins of the Golgi, including enzymes required for glycosaminoglycan (GAG) synthesis, combined with a reduction in the core proteins themselves. Loss of the glycocalyx is likely to be of particular mechanistic importance, since knockdown of galactosyltransferase II (beta-1,3-galactotransferase 6; B3GALT6), the GAG linker-building enzyme, phenocopied the permeability and phenotypic changes induced by mycolactone. Additionally, mycolactone depleted many secreted basement membrane components and microvascular basement membranes were disrupted in vivo during <italic>M. ulcerans</italic> infection in the mouse model. Remarkably, exogenous addition of laminin-511 reduced endothelial cell rounding, restored cell attachment and reversed the defective migration caused by mycolactone. Hence supplementing mycolactone-depleted extracellular matrix may be a future therapeutic avenue, to improve wound healing rates.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mycobacterium ulcerans</kwd><kwd>mycolactone</kwd><kwd>Sec61</kwd><kwd>endothelium</kwd><kwd>basement membrane</kwd><kwd>microvasculature</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>WT202843/Z/16/Z</award-id><principal-award-recipient><name><surname>Simmonds</surname><given-names>Rachel E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM116032</award-id><principal-award-recipient><name><surname>Shi</surname><given-names>Wei Q</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The secreted toxin mycolactone has severe effects on the cells lining blood vessels that will play a critical role in the development of swelling in Buruli ulcer disease.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Buruli ulcer (BU) is a neglected tropical disease caused by subcutaneous infection with <italic>Mycobacterium ulcerans,</italic> characterised by development of large, painless plaques or open lesions, often associated with oedema. The disease is most common in West Africa but is also found in other tropical and subtropical regions including Australia. Although the lesion can be sterilised by a minimum 2-month antimicrobial treatment course with rifampicin and clarithromycin, the wounds can take up to a year to heal and can lead to permanent disfigurement, especially when diagnosed late (<xref ref-type="bibr" rid="bib66">Yotsu et al., 2018</xref>). The polyketide-derived toxin mycolactone, generated by <italic>M. ulcerans</italic>, is the critical driver of BU pathogenesis (<xref ref-type="bibr" rid="bib17">George et al., 1999</xref>; <xref ref-type="bibr" rid="bib50">Sarfo et al., 2016</xref>). Continuous production of this virulence factor causes widespread coagulative necrosis and fibrin deposition in patient skin tissue, as it diffuses through tissue away from the infecting bacteria. Mycolactone is also responsible for the restricted immune response seen in BU. As well as showing long-term cytotoxicity to immune cells (<xref ref-type="bibr" rid="bib17">George et al., 1999</xref>), mycolactone causes a rapid suppression of antigen presentation, co-stimulation and cytokine secretion at low doses (<xref ref-type="bibr" rid="bib21">Guenin-Macé et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Simmonds et al., 2009</xref>).</p><p>Many clinical features of BU can be attributed to the inhibitory action of mycolactone on the Sec61 translocon (<xref ref-type="bibr" rid="bib3">Baron et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Hall et al., 2014</xref>), the complex that translocates most membrane, secretory and organellar polypeptides into the endoplasmic reticulum (ER; <xref ref-type="bibr" rid="bib44">O’Keefe et al., 2022</xref>). In co-translational translocation, nascent proteins are targeted to the ER surface by a signal peptide sequence at the N-terminus; the interaction between the signal peptide and the pore-forming protein of the translocon, Sec61α, opens a central channel that allows access to the ER lumen and a lateral gate through which transmembrane sequences can enter the membrane (<xref ref-type="bibr" rid="bib61">Voorhees and Hegde, 2016</xref>). Mycolactone docks to Sec61, preventing signal peptide engagement and locking the translocon in an inactive state with the lateral gate open but the channel blocked (<xref ref-type="bibr" rid="bib18">Gérard et al., 2020</xref>). The biogenesis of most secretory proteins and Type I and II membrane proteins is inhibited by mycolactone, while polytopic membrane proteins are largely unaffected (<xref ref-type="bibr" rid="bib35">McKenna et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>). Type III and tail-anchored proteins, which utilise alternative translocation pathways (<xref ref-type="bibr" rid="bib43">O’Keefe et al., 2021</xref>), are also resistant to mycolactone (<xref ref-type="bibr" rid="bib24">Hall et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">McKenna et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Grotzke et al., 2017</xref>). The proteins whose translocation into the ER is blocked are synthesized in the cytosol where they are degraded by the proteosome (<xref ref-type="bibr" rid="bib24">Hall et al., 2014</xref>) and selective autophagy (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Gama et al., 2014</xref>). Sec61 blockade induces an integrated stress response by activation of eIF2α kinases (<xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>) and an increase in autophagic flux (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>) and without resolution the cells eventually undergo apoptosis (<xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Bieri et al., 2017</xref>). The time from initial exposure to cell death varies between cell types, but for most human cells takes 3–5 days.</p><p>We have previously shown that endothelial cells are particularly sensitive to mycolactone. At low nanomolar concentrations, mycolactone depletes the anticoagulant receptor thrombomodulin (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>) and junction proteins (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). It also increases the permeability of monolayers formed from endothelial cells derived from both vascular and lymphatic origin (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). While thrombomodulin depletion has also been observed in BU patient skin biopsies (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>), this seems not to be the cause of the widespread fibrin deposition commonly seen within the skin tissue. Instead, this is linked to aberrant staining for the extrinsic clotting pathway initiator tissue factor (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). Tissue factor is normally located in the sub-endothelium where it is segregated from both the plasma proteins that drive coagulation and the surrounding dermal tissue (<xref ref-type="bibr" rid="bib5">Butenas et al., 2009</xref>). However, in BU patients, tissue factor was observed within the connective tissue distant from vessels and this spatially associated with fibrin deposition and early signs of necrosis (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). Our working model leading up to the current work was that mycolactone action at Sec61 in endothelial cells leads to vascular dysfunction and promotes the pathogenesis of BU. The current work seeks to explore the molecular mechanisms driving these events.</p><p>The integrity of the endothelium greatly depends on adequate production and maintenance of the extracellular matrix (ECM) (<xref ref-type="bibr" rid="bib11">Davis and Senger, 2005</xref>), junctional complexes (<xref ref-type="bibr" rid="bib62">Wallez and Huber, 2008</xref>) and the glycocalyx, a highly charged coating of proteoglycans, glycolipids, glycoproteins and glycosaminoglycans (GAG) including heparan sulphate (HS), chondroitin sulphate (CS) and hyaluronic acid (<xref ref-type="bibr" rid="bib68">Zeng et al., 2012</xref>) covering the luminal side of the endothelium (<xref ref-type="bibr" rid="bib49">Reitsma et al., 2007</xref>). The enzymatic glycosylation of heparan and chondroitin sulphate is initiated in the Golgi apparatus by transferase enzymes. This is also the site of the isomerisation and sulfation reactions needed to achieve the rich diversity of GAGs expressed at the cell surface (<xref ref-type="bibr" rid="bib65">Yilmaz et al., 2019</xref>). The glycocalyx acts as an exclusion zone for blood cells and controls interactions with platelets, blood clotting factors and immune cells as well as modulating fluid exchange and acting as a sensory system for the endothelial monolayer (<xref ref-type="bibr" rid="bib65">Yilmaz et al., 2019</xref>). On the basal side of the endothelium, is the basement membrane (BM), an ECM consisting of collagen type IV and laminins, crosslinked by perlecan, a HS proteoglycan, and/or nidogens (<xref ref-type="bibr" rid="bib67">Yousif et al., 2013</xref>). This sheet-like network forms a scaffold that interacts with integrins on the cell surface, controlling structural stability, cell adhesion and angiogenesis as well as preventing leukocyte extravasation (<xref ref-type="bibr" rid="bib67">Yousif et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Song et al., 2017</xref>). Production of these complex structures, which preserve and regulate the barrier between blood and tissue, relies heavily on Sec61-dependent proteins.</p><p>In order to determine the molecular mechanisms driving mycolactone-induced endothelial cell dysfunction, we have undertaken a detailed phenotypic and proteomic study of the changes it induces both in vitro and in vivo. Using primary human dermal microvascular endothelial cells (HDMEC), we found that, as well as increasing monolayer permeability, mycolactone caused rapid changes in endothelial cell morphology and migration, accompanied by loss of glycocalyx, adhesion and ECM proteins. Notably, structurally unrelated Sec61 inhibitors, Ipomoeassin F, and its derivatives induced comparable phenotypes in a similar time frame, highlighting the Sec61 dependency of ECM composition and function. We have dissected the roles of these different components in the response to mycolactone and found that loss of an enzyme critical for GAG biosynthesis phenocopied the changes seen in cell morphology and monolayer permeability. On the other hand, the effects on cell adhesion and migration were dependent on ECM interactions and could be ameliorated by application of exogenous laminin-511. Hence the current work presents a novel pathogenic mechanism in BU, driven by Sec61-dependent effects on endothelial cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Sec61 blockade impacts endothelial cell morphology and adhesion</title><p>We recently observed that mycolactone induces morphological changes in primary endothelial cells in vitro, leading to a dose-dependent increase in monolayer permeability at 24 hr (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). To understand the longer-term effects of mycolactone, we performed time-lapse imaging of HDMECs exposed to mycolactone (<xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref>) or solvent (DMSO) control (<xref ref-type="video" rid="fig1video2">Figure 1—video 2</xref>) every 30 min for 48 hr. As in previous observations, the cells began to take on an ‘elongated’ phenotype after 8 hr. The proportion of elongated cells increased with time (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and after 24 hr exposure, approximately half the cells (51.63 ± 2.89%) had this phenotype. The average ratio of cell length to width doubled in 16 hr, and quadrupled after 24 hr exposure (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). At 24 hr, a small proportion (9.73 ± 4.01%) had acquired a rounded appearance (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) similar to that reported for mycolactone exposure of fibroblasts (<xref ref-type="bibr" rid="bib16">Gama et al., 2014</xref>) and epithelial cells (<xref ref-type="bibr" rid="bib22">Guenin-Macé et al., 2013</xref>). Notably, these cells retained the ability to reattach to the culture vessel (<xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref>), in line with their continued viability in this time window (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>). However, after this time their ability to re-adhere declined and the proportion of detached cells steadily increased. Although the number of rounded cells increased between 24 and 48 hr, the elongated phenotype remained predominant at this time point (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Sec61 inhibition alters primary human endothelial cell morphology and adhesion under static and shear conditions.</title><p>HDMECs were exposed to 10 ng/mL mycolactone (Myco), 0.02% DMSO, 400 nM Ipomoeassin F or 20 nM ZIF-80. (<bold>A–C</bold>). Mycolactone-treated cells were imaged at indicated times in (<bold>A</bold>) and cell numbers of each phenotype (i.e. normal, elongated or rounded) were counted and presented as a percentage of total cell number per field in (<bold>B</bold>) (mean ± SEM of three independent experiments, **, p&lt;0.01, *, p<italic>&lt;</italic>0.05. (<bold>C</bold>) Length and width of each cell exposed to mycolactone for 16 and 24 hr or DMSO for 24 hr per image were measured and presented as a ratio. Data is representative of three independent experiments. ****, p&lt;0.0001 (<bold>D</bold>) A scratch was introduced to a HDMEC monolayer prior to the treatment and visualised at 0, 16, 24 hr. The scratch area is presented as a percentage of the value obtained at 0 hr (mean ± SEM of three independent experiments) ns, not significant, *, p&lt;0.05. Cells exposed to an alternative Sec61 inhibitor ipomoeassin F (IpomF) (<bold>E</bold>) or ZIF-80 (<bold>F</bold>) were imaged at indicated times. Images are representative of three independent experiments. Scale bar = 100 μm. (<bold>G–H</bold>). Live cell imaging was performed with the zenCELL Owl incubator microscope every 30 min over 48 hr. Algorithms of cell coverage (<bold>G</bold>), detached cell numbers (<bold>H</bold>) per time point from three independent experiments are summarised as mean ± SEM. Data presented as cell coverage relative to the value obtained from initial time point (<bold>G</bold>) or a % of detached cells to total cell number (<bold>H</bold>) of each condition. (<bold>I</bold>) Confluent HDMECs under uniaxial shear stress (SHEAR) or not (STATIC) for 24 hr were then exposed to 0.02% DMSO or 10 ng/ml mycolactone. Phase-contrast images were taken 0, 24 and 48 hr later following return to the same conditions. Data is representative of three independent experiments. (<bold>J</bold>). Cell numbers of each phenotype at different time points, presented as a percentage of total cell number per field in (<bold>I</bold>), showing mean of three independent experiments ± SEM, * p&lt;0.05. (<bold>K</bold>). Length and width measurements of cells exposed to mycolactone or DMSO under shear stress conditions for 24 and 48 hr presented as a ratio. Data is representative of three independent experiments. ****, p&lt;0.0001. Statistical analysis was performed by two-way ANOVA (panel <bold>B</bold>, <bold>D and J</bold>) or one-way ANOVA with Dunnett’s (panel <bold>C</bold>) or Tukey’s (panel <bold>D</bold>) correction in GraphPad Prism Version 9.4.1 and 10.2.3. Panel <bold>K</bold>) was analysed using a mixed-effects model with Tukey’s correction for multiple comparisons.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data points used to generate the graphs in <xref ref-type="fig" rid="fig1">Figure 1B, C, D, J and K</xref>.</title><p>Data were generated as described in the respective legend of <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Dose response of HDMEC to mycolactone produced synthetically (Myco-Syn) or purified from natural sources (Myco-Bio).</title><p>Cells were exposed in triplicate to serial dilutions of compound for 96 hr and viability measured with resazurin. Results are expressed as a percentage of the DMSO control. Data from three independent experiments (mean ± SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Images of HDMEC treated with 10 ng/ml synthetic (Syn) or natural (Nat) or 0.02% DMSO.</title><p>Imaging was performed with the zenCELL Owl incubator microscope over 48 hr. Images from selected times are shown. Scale bar = 50 μm. Images are representative of three independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Quantification of cell phenotypes in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title><p>Left panel: Cell numbers of each phenotype were counted and presented as a percentage of total cell number per field (mean ± SD for triplicate wells) *, p&lt;0.05; **, p&lt;0.01, n=1. Right panel: Length and width of cells exposed to mycolactone for 16 and 24 hr or DMSO for 24 hr measured and presented as a ratio. Data is representative of duplicate independent experiments. Statistical analysis was performed by two-way ANOVA in GraphPad Prism Version 9.4.1 and 10.2.3. **, p&lt;0.01; ****, p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Quantification of coverage and detachment in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> using zenCELL Owl algorithms of cell coverage (Left panel), detached cell numbers (Right panel).</title><p>Data represents the mean ± SD for triplicate wells, and is representative of two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig1-figsupp4-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig1-video1.mp4" id="fig1video1"><label>Figure 1—video 1.</label><caption><title>Timelapse video of HDMECs exposed to 10 ng/mL mycolactone.</title><p>Images were taken every 30 min for 48 hr using the zenCELL Owl incubator microscope.</p><p>Time stamp and scale bar as indicated.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig1-video2.mp4" id="fig1video2"><label>Figure 1—video 2.</label><caption><title>Timelapse video of HDMECs exposed to 0.02% DMSO.</title><p>Images were taken every 30 min for 48 hr using the zenCELL Owl incubator microscope. Time stamp and scale bar as indicated.</p></caption></media></fig-group><p>In order to confirm that these phenotypes were relevant to biologically derived mycolactone, we compared the response to the synthetically made mycolactone to that of mycolactone A/B extracted from <italic>M. ulcerans</italic> bacteria. The preparations showed equivalent potency against HDMEC (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and caused similar changes in phenotype in live cell imaging assays (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p><p>Next, we investigated how mycolactone affected HDMEC migration using scratch assays. While control cells were successfully able to close the scratch area within 24 hr, mycolactone-exposed cells displayed a gradual cessation in migration into the cell-free gap (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Thus, while at 16 hr similar numbers of cells had migrated into the scratch regardless of treatment, no further migration could be detected at 24 hr in the presence of mycolactone (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). However, it should be noted that mycolactone has previously been reported to cause cell cycle arrest (<xref ref-type="bibr" rid="bib17">George et al., 1999</xref>), which can be a confounding factor in such migration assays and may explain this finding.</p><p>To determine whether Sec61 inhibition by mycolactone was driving these abnormal phenotypes, we exposed endothelial cells to Ipomoeassin F or its more potent derivative, ZIF-80 (<xref ref-type="bibr" rid="bib72">Zong et al., 2020</xref>). These are structurally distinct to mycolactone but inhibit Sec61α in a very similar manner since they compete for the same binding site (<xref ref-type="bibr" rid="bib71">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Pauwels et al., 2021</xref>). Importantly, both compounds phenocopied the ‘elongated’ appearance preceding detachment in HDMEC within 24 hr (<xref ref-type="fig" rid="fig1">Figure 1E &amp; F</xref>). Unbiased analysis of time-lapse data using zenCELL owl built-in algorithms allowed continuous estimation of cell coverage and detachment, although it could not be trained to recognise the elongated phenotype. As expected, cell coverage increased with time under control conditions, while the proportion of detached cells remained constant at approximately 5%. However, all three Sec61 inhibitors showed similar effects on both readouts (<xref ref-type="fig" rid="fig1">Figure 1G &amp; H</xref>), with a similar effect of biologically purified mycolactone (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Interestingly, both measures remained similar to the control for approximately 24 hr, after which cell coverage declined with a corresponding increase in cell detachment. Taken together, this data strongly supports that these changes are driven by Sec61 inhibition and that endothelial cell homeostasis is dependent on adequate Sec61 function.</p><p>As the responses of endothelial cells grown in static culture plates may not accurately reflect in vivo behaviour where the cells lining blood vessels are subject to shear stress, HDMEC were cultured on an orbital shaker to more closely mimic conditions experienced under flow. Cells were imaged at the periphery of wells where they experience uniaxial shear stress. Cells were grown to confluency and incubated on a rotary shaker for 24 hr then mycolactone was added. Cell elongation and a uniform alignment of the endothelial cells was maintained for 48 hr in the presence of DMSO, as expected (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). By contrast, cells exposed to mycolactone became increasingly disorganised over time and by 48 hr a significant proportion were rounded and detached (42.6%, p&lt;0.05) (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). Although mycolactone did not cause a change in the proportion of elongated cells under these conditions, the pattern of cell rounding was similar to that seen in static cultures (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). There was no detectable difference in the length:width ratio at 24 hr, but by 48 hr mycolactone-exposed HDMEC that remained adhered were significantly elongated compared the DMSO control (p&lt;0.001; <xref ref-type="fig" rid="fig1">Figure 1K</xref>). Thus, although the kinetics are slightly different, the phenotypic changes induced by mycolactone in static culture are reproducible in endothelial cells under flow conditions.</p><p>To establish the in vivo relevance of these findings, we performed fibrinogen immunostaining in the pre-ulcerative mouse footpad model of <italic>M. ulcerans</italic> infection (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Fibrinogen is a high molecular weight (~330 kDa) plasma protein that is normally retained within the lumen of intact vessels and, indeed, in uninfected (vehicle control) mouse feet, fibrinogen was rarely detected, and then only within the vessel lumen (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In contrast, at 21 days post infection (Grade 1 lesions; metatarsal thickness increase ~10%), fibrin(ogen) was seen within the blood vessel wall surrounding the endothelium (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). After 28 days (Grade 2/3 lesions, metatarsal thickness increase 50–100%), widespread fibrin(ogen) staining was seen outside blood vessels within the dermis, in foci consistent with its conversion to insoluble fibrin (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The lack of signal in isotype control-stained tissue (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) confirms the specificity of staining. This penetration of fibrinogen between the endothelial monolayer lining the vessel, then through the vessel wall and conversion to fibrin by other components of the coagulation cascade within deeper tissue is consistent with our previous findings in human BU patient punch biopsies (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). Furthermore, the changes in endothelial cell morphology and monolayer integrity described here and previously <xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref> demonstrates that the extravascular deposition of fibrin is an early feature of infection.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Fibrinogen penetrates the vascular wall at early stages of mouse infection.</title><p>Immunohistochemistry for fibrin(ogen) in the feet of C57BL/6 J mice that received vehicle control (PBS) (A1-2) or intradermal injection of 1x10<sup>5</sup> colony forming units <italic>M. ulcerans</italic> at 21 (Grade 1; B1-3) or 28 days (Grade 3; C1-3) post-infection. Positive fibrin(ogen) staining is brown in colour, the haematoxylin counterstain is purple. Scale bars in A1, B1, and C1: 2 mm; all others: 20 µm. Data representative of three mice at each infection grade, in two independent infections.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Sections stained for acid fast bacilli with Ziehl Neelson stain from mice infected for 21 days (<bold>G1</bold>) or 28 days (<bold>G2</bold>).</title><p>At 21 days immune cell infiltration as well as apparently intracellular bacteria can be clearly seen in proximity to mycobacterial clusters. Scale bars: 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title><italic>M.</italic><italic>ulcerans</italic> infected mouse feet stained with isotype control antibody.</title><p>Scale bars: 20 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig2-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Mycolactone predominantly targets proteins involved in glycosylation and adhesion</title><p>While proteomic studies of mycolactone action have been performed previously (<xref ref-type="bibr" rid="bib3">Baron et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Grotzke et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Gama et al., 2014</xref>), these have used whole cell lysates, leading to systematic limitations in detection of membrane and secreted proteins, due to their relatively low abundance compared to cytosolic proteins. Therefore, to understand the molecular mechanisms driving the pathogenic phenotypic changes in endothelial cells, we instead used a total membrane proteomics approach to enrich for the Sec61 substrates that are targeted by mycolactone.</p><p>We isolated total membrane fractions from HDMECs exposed to DMSO or mycolactone for 24 hr and analysed them by tandem mass tagging (TMT) multiplex LC/MS over biological triplicates (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). A total of 6649 proteins were detected, of which 482 were significantly downregulated and 220 upregulated by mycolactone (&gt;2 Fold change, p&lt;0.05; <xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). Among the total proteins discovered, 36.9% were trafficked via the secretory/endolysosomal pathways that primarily depend on the Sec61 translocon (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This group represented 84.6% of the downregulated but only 23.7% of the upregulated proteins. As predicted, membrane proteins were the most affected in the downregulated group, with little effect on cytoplasmic, cytoskeletal, mitochondrial or nuclear proteins. The downregulated fraction included previously published endothelial targets of mycolactone including coagulation regulators thrombomodulin (TM), von Willebrand Factor (vWF), platelet endothelial cell adhesion molecule (CD31), endothelial protein C receptor and tissue factor pathway inhibitor (TFPI) and cell junction components tyrosine protein kinase receptor TIE1, angiopoietin-1 receptor (TEK), cadherin 5 (CDH5), junctional adhesion molecule 3 (JAM-3) and catenin β1 (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), validating our dataset.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mycolactone causes loss of proteins associated with glycosylation, adhesion and migration in primary human endothelial cells.</title><p>(<bold>A</bold>) Workflow for isolation and proteomic analysis of HDMEC membrane proteins. In three independent replicates, HDMEC were exposed to 10 ng/ml mycolactone or DMSO for 24 hr, lysed by hypotonic lysis and membrane fractions enriched by differential centrifugation as described in Methods. Acetone precipitated proteins were reduced, alkylated and trypsinised then subjected to TMT labelling for quantitative proteomic analysis by LC-MS/MS. (<bold>B</bold>) Volcano Plot of differential expression between DMSO and mycolactone treated samples, plotting mean fold change against false discovery rate adjusted p-values; orange = downregulated, p&lt;0.05; blue = upregulated, p&lt;0.05; black = p &gt; 0.05 (<bold>C</bold>) Pie charts showing subcellular localisation of proteins in total, &gt;twofold upregulated or downregulated (p&lt;0.05) fractions. (<bold>D</bold>) Quantitation of membrane or secreted proteins according to type: blue = upregulated; white = unchanged; orange = downregulated. (<bold>E</bold>) Percentage of downregulated, unchanged and upregulated multi-pass membrane proteins possessing a signal peptide. (<bold>F</bold>) Overlap between mycolactone downregulated endothelial membrane proteome and Sec61-dependent proteome. Venn diagram created using JVenn (<xref ref-type="bibr" rid="bib1">Bardou et al., 2014</xref>), showing overlap in significantly downregulated proteome between the dataset presented here and those obtained in Hela cells treated with siRNA for Sec61α (<xref ref-type="bibr" rid="bib39">Nguyen et al., 2018</xref>). (<bold>G</bold>) Top significantly over-represented (p&lt;0.05) GO groups in downregulated and upregulated data sets, compared to whole genome. Data generated with WebGestalt. (<bold>H</bold>) Quantitation of numbers of up and down regulated proteins in GO groups identified in (<bold>G</bold>).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Mass spectrometry proteomics data for membrane fractions of HDMEC exposed to DMSO or Mycolactone for 24 hr.</title><p>Raw data: HDMEC membrane fraction raw peptide data. Total proteins: Normalised differential expression analysis. Downregulated proteins. Upregulated proteins. Multi-pass membrane proteins &gt;twofold downregulated by mycolactone in HDMEC, with information on whether they have a signal peptide, the amino terminus extracellular, whether they are glycosylated or have at least one long loops (&gt;50aa).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Heat map showing fold change detected in this dataset for previously validated endothelial cell mycolactone targets (<xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>) Dual-colour coding is shown.</title><p>significantly downregulated (p&lt;0.05) or not (p≥0.05) in bold or <italic>Italic,</italic> respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Left panel: Significant association between multipass protein membrane protein signal peptide (SP) ΔG values and level of downregulation by mycolactone (p&lt;0.05).</title><p>Membrane protein type and SP sequence based on Uniprot data, ΔG quantified using ΔG Prediction Server V1.0. Right panel: Impact of distance between signal peptide and first transmembrane domain on susceptibility of multipass proteins to downregulation by mycolactone. Statistical analysis was performed by one-way ANOVA with Tukey’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. *, p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Left panel: Model depicting assisted and unassisted channel opening by signal peptides.</title><p>(<bold>i</bold>) Binding of a nascent chain signal peptide to Sec61α opens a lateral gate into the membrane and causes a shift in the position of the plug domain, allowing access to the ER lumen. (ii) TRAP increases translocation of proteins whose signal peptides bear a high GP content. TRAP is a heterotetrameric complex which interacts with the ribosome on the cytosolic side of the ER membrane and with Sec61α on the luminal side, binding to a hinge region between the N- and C-terminal halves of the protein facilitating channel opening (iii) The Sec62/63 complex is involved in post-translational translocation but can also assist opening of the channel for proteins with signal peptides that gate slowly due to the presence relatively long but less hydrophobic “H-regions” and lower carboxy terminal polarity. This complex also interacts with the ribosome and the translocon and may also interact directly with the nascent peptide chain. In addition, Sec63 recruits BiP to the translocon to further assist channel opening on the luminal side. Right panel: Overlap between mycolactone-downregulated endothelial membrane proteome and translocon-dependent proteome. Venn diagram created using JVenn showing overlap in significantly downregulated proteome between the dataset presented here and those obtained in Hela cells treated with siRNA for Sec61α and translocon associated protein TRAP or HEK293 cells with Sec62 or Sec623 knocked out (<xref ref-type="bibr" rid="bib39">Nguyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Schorr et al., 2020</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Top significantly over-represented (<italic>P</italic>&lt;0.05) Gene Ontology groups in upregulated data set, compared to whole genome.</title><p>Data generated with WebGestalt.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig3-figsupp4-v1.tif"/></fig></fig-group><p>As seen in previous proteomic studies and in vitro translocation assays (<xref ref-type="bibr" rid="bib35">McKenna et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Demangel and High, 2018</xref>; <xref ref-type="bibr" rid="bib34">McKenna et al., 2016</xref>), mycolactone preferentially targeted secreted and single pass type I and type II membrane proteins in endothelial cells, with no effect on the EMC-dependent Type III proteins or the GET pathway-dependent tail-anchored proteins (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). A small number (51 out of 606 detected) of multi-pass membrane proteins were also &gt;twofold downregulated by mycolactone (<xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). This group was relatively enriched for signal peptide-bearing proteins (42% vs 4% amongst unchanged and upregulated multi-pass proteins; <xref ref-type="fig" rid="fig3">Figure 3E</xref>). The rules governing sensitivity of this subgroup to mycolactone appear to be similar to those reported for single pass type I proteins (<xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>), with higher signal peptide hydrophobicity and a shorter distance between the signal peptide and first transmembrane domain being associated with increased resistance to the effects of mycolactone (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Of the remaining mycolactone-sensitive multi-pass proteins, 80% contained at least one long loop (&gt;50 aa) between transmembrane domains. Among the upregulated proteins, 88% of the integral membrane proteins were multi-pass membrane proteins, and only one of the predicted single pass proteins contained a signal peptide. Likewise, the four upregulated secreted proteins identified are all secreted by non-conventional pathways.</p><p>Overall, the data support the recently described model for the biogenesis of multi-pass proteins whereby the majority of multimembrane spanning proteins utilise an alternative translocon that includes Sec61 and the PAT, GEL and BOS complexes but, crucially, bypasses the lateral gate, instead relying on generation of a lipid-filled cavity on the opposite side of Sec61 (<xref ref-type="bibr" rid="bib54">Smalinskaitė et al., 2022</xref>; <xref ref-type="bibr" rid="bib58">Sundaram et al., 2022</xref>). Here, only those multi-pass proteins possessing a signal peptide or long internal loops require insertion into the membrane via the Sec61 channel, and therefore only these are sensitive to mycolactone.</p><p>Our membrane targeted approach identified a higher number of Sec61-dependent proteins in our control cells compared to previous studies (<xref ref-type="bibr" rid="bib3">Baron et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Grotzke et al., 2017</xref>) thus achieving our goal of wider capture of mycolactone-sensitive proteins. Moreover, when compared to siRNA-based Sec61α knockdown in Hela cells, despite the differences in cell type and methodology, 100 of the downregulated proteins were common to both datasets (<xref ref-type="fig" rid="fig3">Figure 3F</xref>; <xref ref-type="bibr" rid="bib39">Nguyen et al., 2018</xref>). While possession of a signal peptide or anchor appears to be crucial to mycolactone sensitivity (<xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>), overall, no specific signal peptide sequence features were associated with downregulation. In keeping with this, there was very little overlap between mycolactone downregulated proteins and those lost following knockdown of translocon-associated proteins TRAPβ or knockout of Sec62/Sec63 (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>; <xref ref-type="bibr" rid="bib39">Nguyen et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Schorr et al., 2020</xref>), which assist gating of the translocon by weak signal peptides. Thus, as suggested by analysis of the structure of the inhibited translocon (<xref ref-type="bibr" rid="bib18">Gérard et al., 2020</xref>), mycolactone acts via direct interaction with the Sec61α signal peptide binding site rather than through interference with accessory proteins.</p><p>Gene ontology (GO) analysis of mycolactone-upregulated proteins supported previous observations by ourselves and others of cellular stress responses, with significant enrichment of terms associated with oxidative stress and detoxification (<xref ref-type="fig" rid="fig3">Figure 3G</xref>; <xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Förster et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Grönberg et al., 2010</xref>). The upregulated proteins also included several proteins involved in the autophagy pathway, including SQSTM1/p62, which is involved in the cellular response to mycolactone (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). However, in the significantly downregulated fraction a distinct pattern emerged, with GO terms associated with glycosylation, matrix organisation, adhesion and cell migration showing the greatest over-representation compared to the whole genome. Within these GO groups, the vast majority of proteins detected in our proteome were downregulated by mycolactone (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Similar results were obtained when the downregulated proteins were compared to the total detected proteome (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>), showing this pattern was not an artefact resulting from membrane enrichment.</p></sec><sec id="s2-3"><title>Mycolactone disproportionately targets Golgi-resident proteins involved in glycosylation and glycosaminoglycan chain synthesis leading to the loss of surface GAGs</title><p>The Golgi is the site of higher order protein glycosylation and GAG synthesis and, of the intracellular organelles, is the most affected by mycolactone (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The Golgi has a particularly high proportion of type II membrane proteins as the membrane anchor and sequences around it can act as a signal for Golgi retention (<xref ref-type="bibr" rid="bib31">Kikegawa et al., 2018</xref>) and nearly all of these Golgi-expressed type II membrane proteins were significantly downregulated by mycolactone (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Interestingly, type II Golgi proteins showed a higher degree of down-regulation by mycolactone than ER or plasma membrane localised type II proteins (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This suggests the signals that lead to Golgi localisation may make proteins more sensitive to Sec61 inhibition, although it is equally possible that Golgi proteins are turned over at a higher rate than those at other sites as depletion is generally at the turnover rate (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>). The effect is not due to differences in transmembrane domain hydrophobicity, which shows little variation and has no impact on Type II protein levels in mycolactone-treated cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Endothelial glycosaminoglycan chain synthesis is blocked by mycolactone in primary human endothelial cells.</title><p>HDMECs exposed to 10 ng/mL of mycolactone (Myco) or 0.02% DMSO for 24 hr or indicated times were subjected to proteomic analysis (<bold>A–D</bold>), surface immunostaining (<bold>E–F, H</bold>) or immunoblotting (<bold>G</bold>). (<bold>A</bold>) Volcano Plot of differential expression between DMSO and mycolactone-treated samples, plotting mean fold change against false discovery rate adjusted <italic>p</italic>-values. Pale blue = total detected proteins; dark blue = Type II membrane proteins; yellow = Golgi-localised Type II membrane proteins. (<bold>B</bold>) Violin plot showing fold change in protein levels for Type II membrane proteins grouped according to subcellular location. ns, not significant; **, p&lt;0.01; ****, p&lt;0.0001. (<bold>C</bold>) Heat map showing fold change in Golgi-localised O- and N-glycosylation enzymes in mycolactone exposed HDMEC. Dual-colour coding is shown, only one unique peptide detected in asterisks, and significantly downregulated (p&lt;0.05) or not (p≥0.05) in bold or <italic>Italic,</italic> respectively. (<bold>D</bold>) Genes in GAG biosynthesis categorised according to function and side chains of chondroitin sulphate/ dermatan sulphate (CS/DS), heparan sulphate (HS) or keratan sulphate (KS). Heatmap showing Log2 fold change of these genes in response to mycolactone in three independent experiments. Dual-colour coding is shown. Genes undetected are indicated as crossed, only one unique peptide detected in asterisks, and significantly downregulated (p&lt;0.05) or not (p≥0.05) in bold or <italic>Italic,</italic> respectively. (<bold>E–F</bold>) Cells were treated with or without chondroitinase ABC (ABC) or heparinase III (HepIII), immunostained with anti-chondroitin sulphate (CS), anti-Δ-heparan sulphate (dHS) antibodies or the isotype controls for flow cytometry analysis. Histogram plot for single cell population of CS (<bold>E</bold>) and dHS (<bold>F</bold>) and the respective mean fluorescence intensity (MFI) are shown. Unstained untreated cells filled grey; isotype control of untreated cells, dashed line in black; untreated cells incubated with chondroitinase ABC prior to CS staining or without HepIII prior to dHS staining, grey line; untreated cells with CS-PE or dHS-PE, black line; cells exposed to DMSO stained with antibodies, blue line; cells exposed to mycolactone stained with antibodies, red line. MFI is presented as a % of untreated control (mean ± SEM of three independent experiments). **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001. (<bold>G</bold>) Cells were lysed, treated with heparinase III and analysed by immunoblotting. HS neoepitopes were visualised with anti- Δ-heparan sulphate (dHS) antibody with the approximate migration of molecular weight markers in kDa. GAPDH used as loading control. Images are representative of three independent experiments. (<bold>H</bold>) Cells were incubated with HepIII, fixed and immunostained with anti-dHS antibody (green), permeabilised and labelled with TRITC-conjugated phalloidin (magenta). Nuclei were stained with DAPI (blue). Images are representative of two independent experiments. Scale bar = 50 μm. Statistical analysis was performed one-way ANOVA with Tukey’s (panel <bold>B</bold>) or Dunnett’s (panel <bold>E</bold>&amp;<bold>F</bold>) correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data points used to generate the graphs in <xref ref-type="fig" rid="fig4">Figure 4E and F</xref>.</title><p>Data were generated as described in the respective legend of <xref ref-type="fig" rid="fig4">Figure 4</xref>.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Annotated immunoblots from <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title><p>Immunoblots for <xref ref-type="fig" rid="fig4">Figure 4G</xref> were performed as described in the legend of <xref ref-type="fig" rid="fig4">Figure 4</xref>. This file shows the full-size blots probed with anti-dHS and anti-GAPDH antibodies for each of three biological repeats (‘2 reps’ and ‘3rd rep’), alongside molecular weight markers and annotated for treatments.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86931-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Raw immunoblots from <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title><p>Immunoblots for <xref ref-type="fig" rid="fig4">Figure 4G</xref> were performed as described in the legend of <xref ref-type="fig" rid="fig4">Figure 4</xref>. This folder contains the raw images collected on the Fusion FX Imager (Vilber-Lourmat) for blots probed with anti-dHS and anti-GAPDH antibodies for each of three biological repeats (‘2 reps’ and ‘3rd rep’).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86931-fig4-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Downregulated intracellular proteins in HDMECs following 24 hr exposure to 10 ng/mL mycolactone, according to subcellular location, presented as percentage of total.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Impact of membrane anchor ΔG values on fold change in expression induced by mycolactone for all identified Type II membrane proteins.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Cartoon representing mycolactone-downregulated steps of GAG enzymatic synthesis.</title><p>Each intermediate product is shown in blue and alongside with its responsible enzyme(s). Candidates significantly downregulated (p&lt;0.05) by mycolactone are shown in red, unchanged in black and undetected in grey. Unique peptide numbers detected in proteome are in purple (underlined).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Detailed analysis of our dataset revealed that targeting of Golgi-localised proteins by mycolactone leads to significantly decreased abundance of multiple enzymes involved in both higher order N- and O-linked glycosylation (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). However, the biggest impact is seen in GAG production, with the majority of the enzymes involved in GAG synthesis lost in mycolactone treated HDMECs (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). All of the 23 proteins in the GAG biosynthetic pathway detected in our analysis are type II membrane proteins and 19 (82%) of these were downregulated by mycolactone (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), affecting every step of glycosaminoglycan production (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Three of the mycolactone-targeted proteins were involved in initial steps of keratan sulphate formation, four in common synthesis initiation of chondroitin sulphate (CS), dermatan sulphate (DS), and heparan sulphate (HS), six in chain elongation of CS/DS and HS (two and four, respectively), and six in epimerisation or sulfation processes that enhance the structural diversity of CS/DS or HS (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><p>Given the importance of GAGs to endothelial function and the dramatic loss in GAG biosynthetic enzymes induced by mycolactone, we evaluated surface levels of the predominant endothelial GAGs, HS, and CS, using flow cytometry on HDMECs exposed to mycolactone for 24 hr. As a control, chondrointinase ABC was used to remove surface CS, resulting in fluorescence levels 60% lower than untreated cells. Remarkably, CS fluorescence intensity was even lower in cells exposed to mycolactone (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Similarly, using an antibody specific for a neoepitope of HS generated by heparinase III digestion, dHS, disrupted surface HS expression was observed in mycolactone-exposed cells (14.11 ± 7.40% vs. DMSO solvent control 105.30 ± 9.79%, p=0.0006, <xref ref-type="fig" rid="fig4">Figure 4F</xref>). In addition, HS-containing proteoglycans were detected by immunoblot using the anti-dHS antibody. Heparinase III digestion revealed an abundance and diversity of heparan sulphate containing proteins present in untreated or DMSO-exposed HDMECs that decreased progressively with mycolactone exposure (<xref ref-type="fig" rid="fig4">Figure 4G</xref>, <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig4sdata3">Figure 4—source data 3</xref>). By immunofluorescence, HS forms a mesh-like network around and between cells in untreated and DMSO solvent controls (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). However, in HDMECs exposed to mycolactone, or ZIF-80, the HS-positive network was disrupted within 20 hr (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Collectively, this data confirms that Sec61 inhibition by mycolactone profoundly impairs the ability of endothelial cells to synthesise GAG chains.</p></sec><sec id="s2-4"><title>Loss of galactosyltransferase II drives changes in endothelial cell morphology and monolayer permeability</title><p>We reasoned that mycolactone-dependant depletion of any enzyme involved in the early stages of GAG biosynthesis would, on its own, be sufficient to explain the loss of HS and CS. Therefore, we validated its effect on the GAG linker building enzyme galactosyltransferase II (B3GALT6) by immunofluorescence. Endothelial B3GALT6 colocalised with the Golgi marker GOLGB1/Giantin in a perinuclear region in untreated cells and was unchanged in those exposed to the solvent control (0.02% DMSO; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). B3GALT6 expression levels remained normal in HDMECs exposed to mycolactone for 6 hr but a clear reduction was seen after 12 hr (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Similar findings were made with biological mycolactone (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Notably, ZIF-80 reduced B3GALT6 expression in a similar manner (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Loss of B3GALT6 affects endothelial cell morphology and monolayer permeability in primary human endothelial cells.</title><p>(<bold>A</bold>) HDMECs exposed to 10 ng/mL mycolactone (Myco) or 0.02% DMSO for indicated times. (<bold>B–G</bold>) HUVECs transfected with si-B3GALT6 or si-negative control (Ctrl) oligos for 48 hr. (<bold>A–B</bold>) Cells were fixed, permeabilised and immunostained with anti-B3GALT6 and anti-GOLGB1 antibodies. B3GALT6 (green) and the Golgi apparatus (magenta) were visualised and nuclei stained with DAPI (blue). Scale bar = 50 μm (20 μm in the crop panels of <bold>A</bold>). Corrected total cell fluorescence of B3GALT6 in Golgi apparatus per cell was measured and presented as a value normalised to the mean value obtained from untreated control of each experiment. More than 30 cells per condition were measured per experiment. Images and quantification are representative of three independent experiments. (<bold>C–E</bold>) HUVECS exposed to 10 ng/mL mycolactone (Myco) or 0.02% DMSO for 24 hr one day post-transfection were imaged by an inverted microscope. (<bold>D</bold>) Length and width of each cell presented as a ratio. At least 100 cells were measured for each treatment. Values are representative of three independent experiments. (<bold>E</bold>) Rounded cell number per image presented as a % of total cell number per condition (values represent the mean ± SEM of three independent experiments). (<bold>F</bold>) Permeability of transfected HUVEC monolayers on inserts with 1 μm pores treated with 100 ng/mL IL-1β, 10 ng/mL mycolactone (Myco) or 0.02% DMSO for 24 hr was quantified. Fluorescence intensity of FITC-dextran in the receiver wells was measured and presented as a % where 100% is the value obtained from transwells lacking a cell monolayer, and 0% is untreated control wells (mean ± SEM of three independent experiments). (<bold>G</bold>) HUVECs were transfected with si-B3GALT6 or si-negative control (si-Ctrl) oligos. A scratch was introduced to the monolayer prior to the treatment (10 ng/mL mycolactone (Myco) or DMSO) and live cell imaging was performed with the zenCELL Owl incubator microscope every 15 min for 30 hr. Migration time in hours (hrs) to reform the monolayer is presented as mean ± SEM (n=3); wells with no visible monolayer at the end point were given a maximum value = 30. ns, not significant; *, p&lt;0.05; ****, p&lt;0.0001. Statistical analysis was performed using one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3 (all analysed panels).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data points used to generate the graphs in <xref ref-type="fig" rid="fig5">Figure 5A, B, D, E, F and G</xref>.</title><p>Data were generated as described in the respective legend of <xref ref-type="fig" rid="fig5">Figure 5</xref>.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>HDMECs exposed to 10 ng/mL synthetic (Myco-Syn) or natural mycolactone (Myco-Bio) or 0.02% DMSO for 24 hr were fixed, permeabilised and immunostained with anti-B3GALT6 and anti-GOLGB1 antibodies.</title><p>B3GALT6 (green) and GOLGB1 (magenta) were visualised and nuclei stained with DAPI (blue). Scale bar = 50 μm (20 μm in the crop panels). Corrected total cell fluorescence of B3GALT6 in Golgi apparatus per cell measured and presented as a value normalised to the mean value obtained from untreated control of each experiment. At least 60 cells per condition were measured. Data is representative of duplicate experiments. Statistical analysis was performed by one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. ****, p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>HDMECs exposed to 10 ng/mL of mycolactone (Myco), 0.02% DMSO, 20 nM ZIF-80 or untreated for 24 hr were fixed, permeabilised and immunostained with anti-B3GALT6 and anti-GOLGB1 antibodies and nuclei stained with DAPI.</title><p>Images are representative of two independent experiments. Scale bar = 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig5-figsupp2-v1.tif"/></fig></fig-group><p>In order to investigate whether loss of B3GALT6 was sufficient to induce the phenotypic changes we saw after mycolactone exposure, we knocked down B3GALT6 in HUVECs using siRNA. The reduction in B3GALT6 protein expression compared to cells transfected with non-targeting si-control RNA (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) was comparable to that caused by mycolactone (~80%). B3GALT6 siRNA-treated cells demonstrated a similar elongated appearance (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and image analysis confirmed a significant increase in the ratio of cell length to width in HUVECs transfected with si-B3GALT6 RNA (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). However, knockdown of B3GALT6 did not recapitulate the cell rounding phenotype (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>We next investigated the potential contribution of B3GALT6 loss to the previously observed mycolactone-induced increase in HDMEC and human dermal lymphatic endothelial cell monolayer permeability (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>). Exposure of mock-transfected HUVEC monolayers to 10 ng/mL mycolactone for 24 hr increased permeability to 23.13 ± 7.38%, an effect comparable to 100 ng/mL IL-1β (21.30 ± 3.48%; <xref ref-type="fig" rid="fig5">Figure 5E</xref>). B3GALT6 knockdown in HUVECs also led to a rise in monolayer permeability (10.08 ± 4.37% and 15.47 ± 1.27% of the values seen in empty wells, p=0.2371 and 0.0367, for two different oligonucleotides, <xref ref-type="fig" rid="fig5">Figure 5F</xref>). Interestingly, B3GALT6 knockdown did not reduce the rate of HUVEC migration in scratch assays (<xref ref-type="fig" rid="fig5">Figure 5G</xref>); instead the cells exhibited a slightly increased healing rate compared to controls.</p></sec><sec id="s2-5"><title>Mycolactone rapidly depletes endothelial surface proteoglycans</title><p>Since loss of GAGs did not explain all the phenotypes observed, we considered the so-called core proteins to which GAGs synthesised in the Golgi are covalently linked to form the proteoglycans. These can be secretory, plasma membrane or GPI-anchored proteins, all of which require the Sec61 translocon for their biogenesis. Our proteome revealed that seven HS, CS, and/or DS-carrying proteoglycans were significantly down-regulated after 24 hr mycolactone exposure (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Mycolactone causes a rapid loss of multiple proteoglycans in primary human endothelial cells.</title><p>HDMECs exposed to 10 ng/mL mycolactone (Myco), 0.02% DMSO or 20 nM ZIF-80 for 24 hr or indicated times. (<bold>A</bold>) Heatmap showing representative data for genes encoding proteoglycans. Dual-colour coding for log2 fold change in response to Myco is shown. Possible attached glycosaminoglycan chains such as heparan sulphate (HS), chondroitin sulphate (CS) or dermatan sulphate (DS) shown. Candidates with one unique peptide detected indicated with asterisks, significantly downregulated (p&lt;0.05) or not (p≥0.05) in bold or <italic>Italic,</italic> respectively. (<bold>B</bold>) Cells were harvested for flow cytometry analysis. Histogram plots for single cell population of HSPG2, GPC1, and BGN. Unstained untreated cells, filled grey; isotype control of untreated cells, dashed black line. untreated cells stained with antibodies, black line; cells exposed to DMSO stained with antibodies, blue line; cells exposed to mycolactone stained with antibodies, red line. MFI is presented as a % of untreated control (mean ± SEM of three independent experiments). **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001. (<bold>C</bold>) Cells were fixed and immunostained with anti-perlecan antibody (green), permeabilised and labelled with TRITC-conjugated phalloidin (magenta). Nuclei were stained with DAPI (blue). Images are representative of three independent experiments. Scale bar = 50 μm. Statistical analysis was performed using one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3 (all analysed panels).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Data points used to generate the graphs in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title><p>Data were generated as described in the respective legend of <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>HUVECs exposed to 10 ng/mL of mycolactone (Myco), 0.02% DMSO or remained untreated for indicated times.</title><p>Cells were harvested for flow cytometry analysis. Histogram plots for single cell population of HSPG2 and GPC1. Unstained, untreated cells, filled grey; isotype control of untreated cells, dashed black line. untreated cells stained with antibodies, black line; cells exposed to DMSO stained with antibodies, blue line; cells exposed to mycolactone for 2, 6, and 24 hr stained with antibodies, pink, orange and red line, respectively. MFI is presented as a % of untreated control (mean ± SEM of three independent experiments). Statistical analysis was performed by one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. ns, not significant; **, p&lt;0.01; ***, p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>HDMECs exposed to 10 ng/mL synthetic (Syn) or natural mycolactone (Nat) or 0.02% DMSO for 24 hr.</title><p>Cells were fixed and immunostained with anti-HSPG2 antibody (green), permeabilised and labelled with TRITC-conjugated phalloidin (magenta). Nuclei were stained with DAPI (blue). Scale bar = 20 μm, Data from one experiment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Confluent HDMECs under uniaxial shear stress for 24 hr were then exposed to 0.02% DMSO or 10 ng/ml mycolactone (Myco) for 48 hr under the same conditions then fixed and stained with anti-HSPG2 antibody (green) and counterstained with DAPI (blue).</title><p>Scale bar = 10 μm, data from one experiment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig6-figsupp3-v1.tif"/></fig></fig-group><p>Using flow cytometry, we validated the changes in abundance of three cell surface proteoglycans; perlecan (HSPG2; secreted, HS/CS), glypican-1 (GPC1; GPI-anchored, HS/CS) and biglycan (BGN; secreted, CS/DS). Syndecan-2, a membrane-bound protein for which only one unique peptide was found in the proteome, could not be detected by flow cytometry. The most profound effects were seen for perlecan and glypican-1 (detection at 10.8 ± 4.8% and 28.8 ± 9.0% of untreated control, <xref ref-type="fig" rid="fig6">Figure 6B</xref>), while biglycan was partly reduced (43.7 ± 6.8% of untreated control). As the turnover rate of HS proteoglycans is rapid t<sub>1/2</sub> = 3–4 hr in granulosa and 6.9 hr in macrophages (<xref ref-type="bibr" rid="bib45">Owens and Wagner, 1991</xref>; <xref ref-type="bibr" rid="bib64">Yanagishita and Hascall, 1984</xref>), we explored the rate of perlecan and glypican-1 loss at early time points in HUVECs. A~50% reduction in perlecan was evident after only 2 hr mycolactone treatment, reaching significance at 6 hr. Depletion of glypican-1 was slower, evident at 6 hr and reaching significance at 24 hr (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><p>Immunofluorescence staining of HDMECs showed abundant perlecan staining in control cells, particularly around intercellular junctions, but the staining rapidly decreased in response to mycolactone, with reduced expression detectable after 8 hr (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). HDMECs exposed to ZIF-80 for 8 hr displayed similarly limited perlecan-positive junctional staining (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), and the depletion was duplicated when biological purified mycolactone was compared to synthetic material (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>), and also occurred when the endothelial cells were under shear stress (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>). The parallel loss of GAGs and the proteoglycans that bear them means that the glycocalyx is severely disrupted by mycolactone.</p></sec><sec id="s2-6"><title>Mycolactone depletes endothelial basement membrane components and their ligands</title><p>Taken together, our results so far show that mycolactone profoundly depletes the endothelial glycocalyx, due to the loss of both GAG and proteoglycan biosynthesis following Sec61 inhibition. However, while loss of GAG production affected permeability, it had less impact on adhesion and migration. We therefore next focused on the downregulated proteins in our dataset with GO classifications linked to these processes. Numerous adhesion molecules and basement membrane components were downregulated by mycolactone, including nidogen 1 (NID1), laminins and collagens (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Although the abundance of major BM component collagen IV was not significantly influenced by mycolactone, perhaps indicating a slow turnover rate, several ER-localised and/or secreted enzymes involved in collagen biosynthesis, were reduced as previously reported in murine fibroblasts (<xref ref-type="bibr" rid="bib16">Gama et al., 2014</xref>). Laminins are the other key constituent glycoproteins of the BM and important binding partners for endothelial cell integrins. Our proteomic data suggested multiple laminins are affected by mycolactone. Laminin α4 and α5 are both common to all types of vessel wall, but α4 has a slightly higher turnover rate (<xref ref-type="bibr" rid="bib53">Sixt et al., 2001</xref>). By immunofluorescence staining, laminin α4 was seen in perinuclear regions within cells and in the network bridging intercellular junctions between endothelial cells in untreated and DMSO control HDMEC (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). After 16 hr of exposure to mycolactone, the perinuclear staining was absent and the laminin-positive network between cells had become disconnected (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Similar findings were made in biological purified mycolactone was compared to synthetic material (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Loss of laminin α4 staining was also observed in endothelial cells exposed to mycolactone under shear stress (Fig <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). The same striking decrease was also seen in HDMECs exposed to ZIF-80 (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mycolactone depletes primary human endothelial adhesion molecules and basement membrane proteins, and damages the basement membrane during mouse infection.</title><p>(<bold>A–C</bold>) HDMECs exposed to 10 ng/mL mycolactone (Myco), 0.02% DMSO or 20 nM ZIF-80 for 24 hr or indicated times. (<bold>A</bold>) Heatmap showing representative data for genes encoding junctional or adhesion molecules, basement membrane components and proteins involved in platelet adhesion. Dual-colour coding for log2 fold change in response to Myco is shown. Candidate with one unique peptide detected is indicated with asterisks, significantly downregulated (p&lt;0.05) or not (p≥0.05) in bold or <italic>Italic,</italic> respectively. (<bold>B</bold>) HDMEC were fixed and immunostained with anti-laminin α4 antibody (green), permeabilised and labelled with TRITC-conjugated phalloidin (magenta). Nuclei were stained with DAPI (blue). Images are representative of two independent experiments. Scale bar = 50 μm. (<bold>C</bold>) HDMEC were harvested for flow cytometry analysis. Histogram plots for single cell population of integrin β1, integrin β4, and laminin α5. Unstained, untreated cells, filled grey; isotype control of untreated cells, dashed black line. untreated cells stained with antibodies, black line; cells exposed to DMSO stained with antibodies, blue line; cells exposed to Myco stained with antibodies, red line. MFI is presented as a % of untreated control (mean ± SEM of three independent experiments). Statistical analysis was performed using one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3; ns, not significant; **, p&lt;0.01; ***, p&lt;0.001. (<bold>D–E</bold>) C57BL/6 J mice were infected with <italic>M. ulcerans</italic> bacteria using the footpad model (<bold>D</bold>) Alcian blue-periodic acid Schiff stain of mice that received vehicle control (PBS) (<bold>D1, D4</bold>) or intradermal injection of 1*10<sup>5</sup> colony forming units <italic>M. ulcerans</italic> at 21 (Grade 1; <bold>D2, D5</bold>) or 28 days (Grade 2/3; D3, D6-7) post-infection. Neutral glycans are indicated by purple staining and acidic glycans by light blue Blood vessel lumens are indicated by an “L”. Scale bars in D1-3: 2 mm; all others: 20 µm. (<bold>E</bold>) Representative transmission electron microscopy scan of grade 1 <italic>M. ulcerans</italic> infected murine footpad. The ultrathin section of glabrous skin shows the pericapillary interstitium slightly expanded, collagen (<bold>c</bold>) fibrils variably disaggregated and infiltrating macrophages (<bold>m</bold>). The endothelial cells (<bold>e</bold>) are reactive and exhibit cytoplasmic projections (*) whilst the basement membrane is multifocally disrupted (arrows). A thin layer of pericytes (<bold>p</bold>) is variably expanded by oedema. Scale bar: 2 μm.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Data points used to generate the graphs in <xref ref-type="fig" rid="fig7">Figure 7C</xref>.</title><p>Data were generated as described in the respective legend of <xref ref-type="fig" rid="fig7">Figure 7</xref>.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig7-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Annotated immunoblots from <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>.</title><p>Immunoblots for <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref> were performed as described in the legend of <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>. This file shows the full-size blots probed with anti-FN1 and anti-GAPDH antibodies for each of three biological repeats (‘rep 1&amp;2’ and ‘rep 3’), alongside molecular weight markers and annotated for treatments.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86931-fig7-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Raw immunoblots from <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>.</title><p>Immunoblots for <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref> were performed as described in the legend of <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>. This folder contains the raw images collected on the Fusion FX Imager (Vilber-Lourmat) for blots probed with anti-FN1 and anti-GAPDH antibodies for each of three biological repeats (‘rep 1&amp;2’ and ‘rep 3’).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86931-fig7-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata4"><label>Figure 7—source data 4.</label><caption><title>Annotated immunoblots from <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>.</title><p>Immunoblots for <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref> were performed as described in the legend of <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>. This file shows the full-size blots probed with anti-ITGA5 and anti-GAPDH antibodies for each of three biological repeats (‘rep a&amp;b’ and ‘rep c’), alongside molecular weight markers and annotated for treatments.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86931-fig7-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata5"><label>Figure 7—source data 5.</label><caption><title>Raw immunoblots from <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>.</title><p>Immunoblots for <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref> were performed as described in the legend of <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>. This file shows the full-size blots probed with anti-ITGA5 and anti-GAPDH antibodies for each of three biological repeats (‘rep a&amp;b’ and ‘rep c’), alongside molecular weight markers and annotated for treatments.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86931-fig7-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>HDMECs exposed to 10 ng/mL synthetic (Myco-Syn) or natural mycolactone (Myco-Bio) or 0.02% DMSO for 24 hrs.</title><p>Cells were fixed and immunostained with anti-LAMA4 antibody (green), permeabilised and labelled with TRITC-conjugated phalloidin (magenta). Nuclei were stained with DAPI (blue). Scale bar = 20 μm, Data from one experiment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Confluent HDMECs under uniaxial shear stress for 24 hr were then exposed to 0.02% DMSO or 10 ng/ml mycolactone (Myco) for 48 hr under the same conditions, then fixed and stained with anti-LAMA4 antibody (green) and counterstained with DAPI (blue).</title><p>Scale bar = 10 μm. Data from one experiment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig7-figsupp2-v1.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>HDMECs exposed to 10 ng/mL of mycolactone (Myco), 0.02% DMSO or remained untreated for indicated times.</title><p>Cells were lysed and subjected to immunoblotting with anti-FN1 antibodies. Each immunoblot intensity was normalised according to GAPDH and untreated controls. Statistical analysis was performed by one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. ****, p&lt;0.0001. Data from three independent experiments (mean ± SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig7-figsupp3-v1.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>HDMECs exposed to 10 ng/mL of mycolactone (Myco), 0.02% DMSO or remained untreated for indicated times.</title><p>Cells were lysed and subjected to immunoblotting with anti-ITGA5 antibodies. Each immunoblot intensity was normalised according to GAPDH and untreated controls. Statistical analysis was performed by one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. ns, not significant; **, p&lt;0.01. Data from three independent experiments (mean ± SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig7-figsupp4-v1.tif"/></fig></fig-group><p>The effect of mycolactone on the abundance of the laminin binding integrin β subunits β1 and β4 and laminin α5 in HDMEC were determined by flow cytometry (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). After 24 hr, they were reduced to 45.0 ± 6.2%, 27.3 ± 7.7% and 15.6 ± 5.4% respectively of control levels (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). In addition, the loss of expression of the basement membrane component fibronectin and cell surface integrin α5 were validated using immunoblot analysis; fibronectin levels decreased very rapidly showing &gt;75% depletion after 4 hr exposure to mycolactone (p&lt;0.01; <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="fig7sdata2">Figure 7—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig7sdata3">Figure 7—source data 3</xref>) whilst the level of integrin α5 decreased more slowly, reaching ~50% of control levels at 24 hr (p&lt;0.01; <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>, <xref ref-type="supplementary-material" rid="fig7sdata4">Figure 7—source data 4</xref>, <xref ref-type="supplementary-material" rid="fig7sdata5">Figure 7—source data 5</xref>).</p><p>To determine whether the basement membrane was disrupted in vivo, we stained the tissue sections from <italic>M. ulcerans</italic>-infected mice with the alcian blue-periodic acid Schiff (AB-PAS) method. In mouse feet receiving the vehicle control (<xref ref-type="fig" rid="fig7">Figure 7D1</xref>), the dermis contained neutral glycans (purple staining) and the vasculature displayed an intact vessel basement membrane (<xref ref-type="fig" rid="fig7">Figure 7D4</xref>, insert). At early stages of infection (Grade 1; <xref ref-type="fig" rid="fig7">Figure 7D2</xref>), immune cell infiltration could be seen in these regions in proximity to mycobacterial clusters (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and the surrounding dermal tissue had become more acidic (blue staining; <xref ref-type="fig" rid="fig7">Figure 7D5</xref>). At later stages of infection, when the metatarsal area was more swollen (<xref ref-type="fig" rid="fig7">Figure 7D3</xref>) and the dermis showed marked oedema and the fibrous architecture was disrupted (<xref ref-type="fig" rid="fig7">Figure 7D6–7</xref>), there was an overall reduction in the intensity of staining around the vasculature and the vessel basement membranes were irregular (<xref ref-type="fig" rid="fig7">Figure 7D6</xref>, insert).</p><p>To confirm the impact of infection on the basement membrane we used transmission electron microscopy (<xref ref-type="fig" rid="fig7">Figure 7E</xref>) to characterize the early vascular changes in the podal dermis of mice inoculated with <italic>M. ulcerans</italic>. Multiple transverse, oblique and longitudinal sections of arterioles, venules and lymphatics were examined. In Grade 1, the interstitium surrounding the capillary was expanded by electron-lucent granular material, pericyte processes were often separated and collagen fibrils close to the blood vessels increasingly disaggregated. The endothelial cells exhibited varying degrees of swelling and vacuolation with an irregular luminal surface including cytoplasmic undulation and projections. The subendothelial basement membrane appeared multifocally disrupted, expanded or discontinuous (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, arrows). Taken together the data shows that even at early stages of infection, the endothelial basement membrane is compromised and the loss of constituent proteins caused by mycolactone is likely a major factor in these changes.</p></sec><sec id="s2-7"><title>Exogenous laminin-α5 ameliorates mycolactone-driven cell detachment and impaired migration</title><p>Since laminins are secreted proteins, which are then deposited to form cell-associated extracellular matrix, we wondered whether exogenous provision of these molecules might protect mycolactone-exposed cells. We therefore coated tissue culture plates with laminin-111,–411 or –511, complexes that contain laminin β1γ1 in combination with laminins α1, α4, or α5 respectively. As expected (<xref ref-type="bibr" rid="bib13">Di Russo et al., 2017</xref>), primary HDMECs efficiently re-attached to laminin-511-coated culture vessels, with very little reattachment to uncoated vessels (p=0.0020, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). Re-attachment to laminin-411 or the non-endothelial specific laminin-111 was also observed albeit to a lesser extent (p=0.1226 and 0.3365 compared to the uncoated wells, respectively). We then quantified the re-attachment of endothelial cells that had been pre-exposed to mycolactone for 24 hr compared to controls (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Remarkably, mycolactone-exposed cells re-adhered to specifically to laminin-511- (but not 411- or 111-) coated vessels with the same efficiency as controls (<xref ref-type="fig" rid="fig8">Figure 8A</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Laminin α5 ameliorates mycolactone-driven primary human endothelial cell detachment and impaired migration.</title><p>Endothelial cells exposed to 10 ng/mL mycolactone (Myco) or 0.02% DMSO for 24 hr or indicated times. (<bold>A</bold>) Treated HDMECs were harvested and re-seeded to laminin-511, 411, 111 or uncoated plates. After an hour, unbound cells were washed away and attached cells were imaged and cell numbers per field are presented as mean ± SEM of three independent experiments. (<bold>B–D</bold>) Endothelial cells seeded onto laminin-511 or uncoated plates were exposed to mycolactone (Myco) or DMSO. (<bold>B–C</bold>) HDMECs were imaged every 30 min over 48 hr. Rounded or attached cells per condition were counted at 0, 24, 36, 48 hr. Data are presented as a % of total cell number of each condition (<bold>B</bold>) or normalised to the attached cell number counted at 0 hr (<bold>C</bold>) (mean ± SEM of three independent experiments). (<bold>D</bold>) A scratch was introduced to a HUVEC monolayer prior to treatment. The wounded area was imaged every 15 min for 24 h. Scale bar: 200 μm. Cells migrating into the original scratch area were counted at 0, 8, and 16 hr. Data are presented as cell count per scratch area (mean ± SEM of three independent experiments). ns, not significant; *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001; ****, p&lt;0.0001. Statistical analysis was performed in GraphPad Prism Version 9.4.1 and 10.2.3 using two-way ANOVA with Tukey’s correction for multiple comparisons (all analysed panels; panels <bold>B</bold>&amp;<bold>C</bold> also included the Geisser Greenhouse correction for sphericity).</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Data points used to generate the graphs in <xref ref-type="fig" rid="fig8">Figure 8A, B, C and D</xref>.</title><p>Data were generated as described in the respective legend of <xref ref-type="fig" rid="fig8">Figure 8</xref>.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86931-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>HDMECs were harvested and layered to laminin-511, 411, 111 or uncoated wells for one hour.</title><p>Non-adherent cells were washed away and attached cells per field were counted. Data from three independent experiments (mean ± SEM). Statistical analysis was performed by a repeated measures one-way ANOVA with Dunnett’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. *, p&lt;0.05; ***, p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig8-figsupp1-v1.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>HDMEC seeded onto laminin-411, 111 or uncoated plates were exposed to mycolactone (Myco) or DMSO and imaged every 30 min over 48 hr.</title><p>Rounded or attached cells per condition were counted at 0, 24, 36, 48 hr. Data are presented as a % of total cell number of each condition (Left panel) or normalised to the attached cell number counted at 0 hr (Right panel). Statistical analysis was performed by a two-way ANOVA with Tukey’s correction for multiple comparisons and the Geisser Greenhouse correction for sphericity in GraphPad Prism Version 9.4.1 and 10.2.3. Data from three independent experiments (mean ± SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig8-figsupp2-v1.tif"/></fig><fig id="fig8s3" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 3.</label><caption><title>HDMECs seeded onto different laminin isoforms were untreated or exposed to 0.02% DMSO or 10 ng/mL mycolactone (Myco) for 48 hr.</title><p>Their viability was assessed using CellEvent detection kit as described in <xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>. The number of live cells (negative for both active caspase 3/7 and PI) in three fields was determined and expressed as a proportion of total cells. Data from three independent experiments (mean ± SEM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig8-figsupp3-v1.tif"/></fig><fig id="fig8s4" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 4.</label><caption><title>A scratch was introduced to a HUVEC monolayer prior to treatment.</title><p>The wounded area was imaged every 15 min for 24 hr. Scale bar: 200 μm. Cells migrating into the original scratch area were counted at 0, 8, and 16 hr. Data are presented as cell count per scratch area (mean ± SEM of three independent experiments). Statistical analysis was performed by a two-way ANOVA with Tukey’s correction for multiple comparisons in GraphPad Prism Version 9.4.1 and 10.2.3. ns, not significant; **, p&lt;0.01; ***, p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86931-fig8-figsupp4-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig8-video1.mp4" id="fig8video1"><label>Figure 8—video 1.</label><caption><title>Scratch repair in HUVECs exposed to 0.02% DMSO.</title><p>A scratch was introduced to the monolayer and live cell imaging was performed with the zenCELL Owl incubator microscope every 15 min for 23 hr. Time-lapse videos (representative of three independent experiments) were generated with zencell-owl software. Time stamp and scale bar as indicated.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig8-video2.mp4" id="fig8video2"><label>Figure 8—video 2.</label><caption><title>Scratch repair in HUVECs exposed to 10 ng/mL mycolactone.</title><p>A scratch was introduced to the monolayer and live cell imaging was performed with the zenCELL Owl incubator microscope every 15 min for 23 hr. Time-lapse videos (representative of three independent experiments) were generated with zencell-owl software. Time stamp and scale bar as indicated.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig8-video3.mp4" id="fig8video3"><label>Figure 8—video 3.</label><caption><title>HUVECs were seeded on to laminin-511 coated well.</title><p>The following day, a scratch was introduced to the monolayer and the cells were exposed to 10 ng/mL mycolactone. Live cell imaging was then performed with the zenCELL Owl incubator microscope every 15 min for 23 hr. Time-lapse videos (representative of three independent experiments) were generated with zencell-owl software. Time stamp and scale bar as indicated.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig8-video4.mp4" id="fig8video4"><label>Figure 8—video 4.</label><caption><title>HUVECs were seeded on to laminin-411 coated well.</title><p>The following day, a scratch was introduced to the monolayer and the cells were exposed to 10 ng/mL mycolactone. Live cell imaging was then performed with the zenCELL Owl incubator microscope every 15 min for 23 h. Time-lapse videos (representative of three independent experiments) were generated with zencell-owl software. Time stamp and scale bar as indicated.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-86931-fig8-video5.mp4" id="fig8video5"><label>Figure 8—video 5.</label><caption><title>HUVECs were seeded on to laminin-111 coated well.</title><p>The following day, a scratch was introduced to the monolayer and the cells were exposed to 10 ng/mL mycolactone. Live cell imaging was then performed with the zenCELL Owl incubator microscope every 15 min for 23 hr. Time-lapse videos (representative of three independent experiments) were generated with zencell-owl software. Time stamp and scale bar as indicated.</p></caption></media></fig-group><p>We then investigated whether exogenous laminin-511 could ameliorate the cell rounding, attachment or migration phenotypes observed in response to mycolactone using time-lapse imaging of HDMECs. On uncoated wells, mycolactone caused the expected phenotypic changes (<xref ref-type="fig" rid="fig8">Figure 8B–C</xref>), and remarkably, exogenous laminin α5 significantly reduced mycolactone-driven cell rounding, even after 48 hr (7.7 ± 1.5% vs 17.6 ± 2.4%, p=0.0153, <xref ref-type="fig" rid="fig8">Figure 8B</xref>). Similarly, while the relative number of attached cells did not increase steadily with time as for the DMSO control (<xref ref-type="fig" rid="fig8">Figure 8C</xref>), laminin-511 coating prevented the decrease in attached cells seen between 36 and 48 hr in uncoated wells (p=0.0123). These effects were absent in laminin-411 and –111-coated wells (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>). Laminin coating did not impact HDMEC survival in the presence or absence of mycolactone at 48 hr (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>), although as mentioned before, cell death due to mycolactone is minimal prior to 72 hr (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>).</p><p>For migration, we performed a scratch assay on HUVECs in wells coated or not with laminins prior to mycolactone exposure. Monitoring cell migration using time-lapse imaging revealed that control HUVECs took less than 16 hr to close a 600–800 µm gap (<xref ref-type="video" rid="fig8video1">Figure 8—video 1</xref>). By contrast, the leading edge of wounded HUVEC monolayers exposed to mycolactone gradually stopped migrating into the cell-free region after ~7 hr; at this point the cells began to migrate randomly before undergoing the previously described morphological changes (<xref ref-type="video" rid="fig8video2">Figure 8—video 2</xref>). However, strikingly, in HUVEC monolayers plated onto laminin-511, cells continued to migrate into the gap in the presence of mycolactone, with a leading edge still evident after 16 hr (<xref ref-type="video" rid="fig8video3">Figure 8—video 3</xref>). Cell counts per unit scratch area at 8 and 16 hr showed that cells plated onto laminin-511 were able to migrate back at a rate comparable to that seen in monolayers exposed to DMSO in uncoated wells (<xref ref-type="fig" rid="fig8">Figure 8D</xref>, p=0.286). We did not see these same effects on laminin-411 and –111-coated wells (<xref ref-type="video" rid="fig8video4">Figure 8—video 4</xref> and <xref ref-type="video" rid="fig8video5">Figure 8—video 5</xref>) where migration rates remained significantly lower than the control (p=0.0054 and 0.0003, respectively, <xref ref-type="fig" rid="fig8s4">Figure 8—figure supplement 4</xref>).</p><p>This ability of laminin α5 to reverse or diminish the impact of mycolactone on endothelial cell adhesion, morphology and migration highlights the contribution of the loss of basement membrane proteins to the phenotypic changes induced by mycolactone and presents an unanticipated potential for use in wound care in Buruli ulcer skin lesions, although such therapies are currently in their infancy (<xref ref-type="bibr" rid="bib29">Iorio et al., 2015</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Until recently, the pathogenesis of BU was thought to rely on two factors; immunosuppression due to the action of mycolactone on innate and adaptive immunity, and direct cytotoxic action of mycolactone on the cells present within the subcutis leading to cell death and necrosis. Our findings provide further evidence supporting a third and vital pathway to tissue necrosis; the induction of endothelial dysfunction that drives an indirect mechanism leading to tissue necrosis via the breakdown of vessel integrity and fibrin-driven ischemia within tissue.</p><p>The current work reaffirms the critical role that Sec61 inhibition plays in the virulence mechanism of mycolactone. In this post-transcriptional, co-translational mechanism responsible for changes in protein abundance, proteins are made in the wrong cellular compartment (the cytoplasm) and degraded by the ubiquitin-proteasome system or removed by autophagy (<xref ref-type="bibr" rid="bib24">Hall et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>). During the current studies we tried, without success, to express examples of our library of SEC61A1 mutants that confer resistance to mycolactone (<xref ref-type="bibr" rid="bib18">Gérard et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>) in primary endothelial cells. This suggests that the endothelium is particularly sensitive to functional perturbation of the Sec61 translocon and perhaps explains why these cells are so exquisitely sensitive to the compound. As an alternative approach, we tested two analogues of the structurally unrelated Sec61 inhibitor Ipomoeassin F that was first isolated as a natural product of the ‘Morning Glory’ flower (<xref ref-type="bibr" rid="bib71">Zong et al., 2019</xref>). Across multiple readouts, this induced comparable phenotypes to mycolactone, in the same time frame, including changes in morphology, loss of GAGs, matrisome proteins required for their synthesis, proteoglycan core proteins and basement membrane proteins. Hence, we are confident that the primary target of mycolactone in endothelial cells is Sec61, as it has already been shown in immune cells (<xref ref-type="bibr" rid="bib3">Baron et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Hall et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Grotzke et al., 2017</xref>), fibroblasts (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>) and epithelial cells (<xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>). Since epithelial cells showed similar effects on migration to those we report here, these effects probably depend on its action on the Sec61 translocon rather than other previously proposed mechanisms such as WASP activation (<xref ref-type="bibr" rid="bib22">Guenin-Macé et al., 2013</xref>).</p><p>Although the Sec61 translocon is thought to be required for the biosynthesis of approximately 30% of the proteome, mycolactone only inhibits production of specific subsets of proteins that traffic through the ER. As their depletion rate depends on protein turnover, inhibitory effects cannot be predicted a priori. Therefore, we performed quantitative proteomic analysis of total membrane fractions of primary endothelial cells to identify as many of the targets of mycolactone as possible, since ‘whole cell’ approaches can bias against membrane proteins, particularly insoluble ones. Indeed, this approach was successful, more than doubling the number of detected proteins classified as membrane, secretory, ER/ERGIC, Golgi or endolysosomal compared to previous studies (<xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>). Significant depletion of our previously discovered protein targets including loss of CDH5, TIE-1, TEK, JAM-C, CD31, vWF, TFPI, and TM (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>), and induction of SQSTM1/p62 (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>) validates this data set. The pattern of protein topologies affected by mycolactone reflected that seen in in vitro translocation assays and whole cell proteome analysis (<xref ref-type="bibr" rid="bib3">Baron et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">McKenna et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Gama et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">McKenna et al., 2016</xref>), further supporting mycolactone selectivity towards secreted, Type I and Type II single pass membrane proteins, with few multi-pass proteins and no Type III or tail- anchored membrane proteins showing any reduction in expression.</p><p>GO analysis confirmed induction of cytoplasmic/oxidative stress responses (<xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Förster et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Kwaffo et al., 2021</xref>) amongst &gt;220 up-regulated proteins in mycolactone-exposed endothelial cells. However, in this work, we focussed on the &gt;480 down-regulated proteins, which represented a striking inadequacy in components of glycoprotein biosynthesis and metabolism and ECM organization, many of which we have validated individually. Taking together the cellular compartment analysis and our understanding of mycolactone’s cellular target, we were able to correctly hypothesise that the effects on endothelial cell function were exacerbated by loss of Golgi-localised Type II transmembrane enzymes involved in GAG (CS, DS, and HS) production. Up to now, the impact of mycolactone on Golgi function has been underappreciated, but the wider ranging effect on protein glycosylation may explain why mycolactone has such a strong effect on glycosylated protein production irrespective of topology (<xref ref-type="bibr" rid="bib24">Hall et al., 2014</xref>). It also suggests that the effects of mycolactone may be even more far-reaching than expected, as even molecules resistant to the Sec61 blockade at the protein level may be functionally affected due to the loss of glycosylation.</p><p>Since GAG biosynthesis is a sequential process, and the endothelial glycocalyx is essential to maintain monolayer permeability (<xref ref-type="bibr" rid="bib27">Harding et al., 2019</xref>), we reasoned that loss of one of the GAG linker-building enzymes common to CS, DS, and HS could be sufficient to explain the mycolactone-induced phenotype. This was supported by siRNA-mediated knockdown of B3GALT6, which transfers galactose to substrates such as galactose-beta-1,4-xylose, that is the third step in this process. B3GALT6 knockdown phenocopied the elongated appearance seen in primary endothelial cells exposed to mycolactone. The intermediate phenotype seen in some experiments suggests that depletion of junctional molecules by mycolactone (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>), also plays an important contributory role. In the context of BU, it is interesting to note that children born with ‘linkeropathies’, who have a reduced ability to synthesise GAG linker regions (<xref ref-type="bibr" rid="bib8">Colman et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Mihalic Mosher et al., 2019</xref>), display phenotypes such as skin fragility and delayed wound healing (<xref ref-type="bibr" rid="bib33">Malfait et al., 2013</xref>) that are similar to antibiotic-treated <italic>M. ulcerans</italic> infections. As well as increasing permeability, the loss of the glycocalyx could exacerbate the inhibition of leukocyte homing caused by mycolactone (<xref ref-type="bibr" rid="bib21">Guenin-Macé et al., 2011</xref>). Notably other viral and bacterial pathogens promote colonisation by degrading the endothelial glycocalyx (<xref ref-type="bibr" rid="bib48">Puerta-Guardo et al., 2016</xref>; <xref ref-type="bibr" rid="bib6">Chiu et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Tang et al., 2021</xref>); however, here the mechanism is via inducing the production of heparanase and other proteinases.</p><p>Importantly, it is not only the GAGs of the apical glycocalyx that are depleted by mycolactone. Many proteoglycan core proteins are also lost. The secretory protein perlecan is notable for being a component of the glycocalyx as well as the BM and was profoundly and rapidly lost from the surface of primary endothelial cells following mycolactone exposure. Other BM components, particularly laminins and their cellular receptors, were also found to be depleted. Excitingly, providing an exogenous coating of laminin α5-containing laminin-511 complex to tissue culture wells protected endothelial cells from mycolactone-driven changes, improving adhesion, and reversing the migration defect. We have not been able to ascribe this to the retention of a specific adhesion molecule, and instead postulate that rescue could be via residual expression of a wide variety of laminin α5 receptors. This is supported by previous work showing that laminin α5 is more promiscuous than laminin α4 (<xref ref-type="bibr" rid="bib13">Di Russo et al., 2017</xref>).</p><p>Adequate adhesion to the BM is critical for endothelial cell proliferation, migration, morphogenesis and survival (<xref ref-type="bibr" rid="bib11">Davis and Senger, 2005</xref>). Furthermore, loss of perlecan and laminin α4, or reduced binding to fibronectin, disturbs the structural integrity and maturation of microvessels (<xref ref-type="bibr" rid="bib60">Thyboll et al., 2002</xref>; <xref ref-type="bibr" rid="bib23">Gustafsson et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Nicosia et al., 1993</xref>), Finally, laminin α5 not only guides tissue patterning (<xref ref-type="bibr" rid="bib57">Spenlé et al., 2013</xref>) and development (<xref ref-type="bibr" rid="bib37">Miner et al., 1998</xref>) but also maintains vascular homeostasis by stabilising endothelial cell tight junctions (<xref ref-type="bibr" rid="bib56">Song et al., 2017</xref>). Therefore, it is perhaps not surprising that we found the BM to be disturbed in <italic>M. ulcerans</italic> infected footpads. Moreover, this was seen in more advanced infections where fibrin deposition was also present within tissue, due to disturbance of the boundary between damaged vessels and dermal connective tissue. It is possible that these effects are exacerbated by IL-1β in vivo; this Sec61-independent pro-inflammatory cytokine has been shown to be induced in macrophages by mycolactone and <italic>M. ulcerans</italic> (<xref ref-type="bibr" rid="bib15">Foulon et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Hall et al., 2021</xref>) and is known to have profound effects on endothelial cell function, including the downregulation of anticoagulant and junctional proteins, induction of vascular permeability and upregulation of BM degrading proteinases (<xref ref-type="bibr" rid="bib10">Cottam et al., 1996</xref>). There is considerable overlap in the endothelial cell responses to IL-1β and mycolactone, although the former’s effects are mediated predominantly at the transcriptional level. An additive effect of mycolactone has been shown for some of these phenotypes in vitro (<xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Hsieh et al., 2022</xref>), although the in vivo situation is likely more complex (<xref ref-type="bibr" rid="bib25">Hall et al., 2021</xref>).</p><p>In summary, this study identifies loss/disruption of the endothelial glycocalyx and BM as a critical molecular process in the pathogenesis of Buruli ulcer. These effects were the same with mycolactone extracted from <italic>M. ulcerans</italic> bacteria and chemically synthesised material, supporting the physiological relevance of our findings. Since these changes occur prior to mycolactone-driven apoptosis (<xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Bieri et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>), they provide further support for our working model whereby mycolactone builds a hyper-coagulative environment alongside disruption of the endothelial monolayer and BM integrity. We propose that this leads to leakage of high molecular weight plasma proteins into the connective tissue where they activate the coagulation cascade leading to fibrin deposition and tissue ischemia. The detection of extravascular fibrinogen at early stages of infection prior to widespread tissue damage and necrosis provides further evidence that endothelial dysfunction could be a driver of disease progression. Rethinking of BU as a vascular disease may ultimately lead to improved therapies that support better wound healing, alongside antibiotic treatment. However, it should be remembered that tissue repair requires a controlled progression through a series of different stages <xref ref-type="bibr" rid="bib2">Barker and Engler, 2017</xref>; following injury, under normal circumstances, platelet accumulation in a fibrin and fibronectin rich matrix is followed by an inflammation phase (<xref ref-type="bibr" rid="bib7">Clark et al., 1982</xref>). Therefore, ameliorating the coagulative features with anticoagulants alongside the standard antimycobacterial drugs may be of most value in the initial stages of treatment, while bioactive dressings containing laminin-derived peptides might be more useful to promote healing at later stages. In this context, laminin-derived bioactive peptides have recently been proposed as a treatment for defective tissue repair (<xref ref-type="bibr" rid="bib29">Iorio et al., 2015</xref>) and indeed, accelerate re-epithelialisation in wounds of diabetic animals (<xref ref-type="bibr" rid="bib69">Zhu et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Ishihara et al., 2018</xref>), suggesting this novel approach may be an effective complement to current therapies and could alleviate the long wound healing times experienced by BU patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>, female)</td><td align="left" valign="bottom">C57BL/6 J</td><td align="left" valign="bottom">Charles River</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:MGI:3028467">MGI:3028467</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. ulcerans</italic>)</td><td align="left" valign="bottom">Mu_1082</td><td align="left" valign="bottom">Richard Phillips, KCCR, Ghana</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (Human primary cells)</td><td align="left" valign="bottom">HUVEC</td><td align="left" valign="bottom">PromoCell</td><td align="left" valign="bottom">C-12200</td><td align="left" valign="bottom">Single Donor</td></tr><tr><td align="left" valign="bottom">Cell line (Human primary cells)</td><td align="left" valign="bottom">HDMEC</td><td align="left" valign="bottom">PromoCell</td><td align="left" valign="bottom">C-12210</td><td align="left" valign="bottom">Juvenile, Single Donor, male</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-fibrinogen<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Agilent DAKO</td><td align="left" valign="bottom">A0080<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2894406">AB_2894406</ext-link></td><td align="left" valign="bottom">IHC: (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotinylated anti-rabbit IgG (horse polyclonal)</td><td align="left" valign="bottom">Vector laboratories</td><td align="left" valign="bottom">BP-100–50<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3661924">AB_3661924</ext-link></td><td align="left" valign="bottom">IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-human Δ-HS (mouse monoclonal F69-3G10)</td><td align="left" valign="bottom">AMSBIO</td><td align="left" valign="bottom">370260 S<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10892311">AB_10892311</ext-link></td><td align="left" valign="bottom">FACS (1:200)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-chondroitin sulphate (mouse monoclonal CS56)</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">C8035<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_476879">AB_476879</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-perlecan (mouse monoclonal 7B5)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">13–4400<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_86311">AB_86311</ext-link></td><td align="left" valign="bottom">FACS (1:200)<break/>IFA (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-glypican-1 (goat polyclonal)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">AF4519<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2232505">AB_2232505</ext-link></td><td align="left" valign="bottom">FACS (2.5 µg/10<sup>6</sup> cells)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-integrin β4/CD104 (rat monoclonal 439-9B)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">14-1049-82<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1210460">AB_1210460</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-integrin β1/CD29 (mouse monoclonal P4C10)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">NBP2-36561<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3295906">AB_3295906</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-syndecan-2 (rat monoclonal 305515)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">MAB2965<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2182871">AB_2182871</ext-link></td><td align="left" valign="bottom">FACS (0.25 µg/10<sup>6</sup> cells)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-biglycan (goat polyclonal)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">AF2667<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2065204">AB_2065204</ext-link></td><td align="left" valign="bottom">FACS (0.1 µg/10<sup>6</sup> cells)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-laminin α5 (mouse monoclonal CL3118)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">NBP2-42391<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3306362">AB_3306362</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-laminin α4 (sheep polyclonal)</td><td align="left" valign="bottom">Biotechne</td><td align="left" valign="bottom">AF7340<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3644426">AB_3644426</ext-link></td><td align="left" valign="bottom">IFA (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Isotype control (mouse monoclonal IgG1κ P3.6.2.8.1)</td><td align="left" valign="bottom">Thermo Fisher Scientific<break/>(Invitrogen)</td><td align="left" valign="bottom">14-4714-81<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_470110">AB_470110</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Isotype control (mouse monoclonal IgG2b)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">MG2B00<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2921189">AB_2921189</ext-link></td><td align="left" valign="bottom">As appropriate (same as test Ab)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Isotype control (polyclonal goat IgG)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">AB-108-C<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_354267">AB_354267</ext-link></td><td align="left" valign="bottom">As appropriate (same as test Ab)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Isotype control rat monoclonal IgG2bκ (eB149/10H5)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">14-4031-81<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_470098">AB_470098</ext-link></td><td align="left" valign="bottom">As appropriate (same as test Ab)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Isotype control (mouse monoclonal IgM, clone PFR-03)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">MA1-10438<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2536806">AB_2536806</ext-link></td><td align="left" valign="bottom">As appropriate (same as test Ab)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE-F(ab’)2-anti-mouse IgG (rat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">12-4010-82<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_11063706">AB_11063706</ext-link></td><td align="left" valign="bottom">As appropriate</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC-anti-goat IgG (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A16000<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2534674">AB_2534674</ext-link></td><td align="left" valign="bottom">As appropriate</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC-anti-rat IgG (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">31629<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_228240">AB_228240</ext-link></td><td align="left" valign="bottom">As appropriate</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-fibronectin (rabbit polyclonal)</td><td align="left" valign="bottom">Merck Millipore</td><td align="left" valign="bottom">AB1945<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2231910">AB_2231910</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-integrin α5 (mouse monoclonal IgG1κ A-11)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-166665<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2280538">AB_2280538</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-Anti-rabbit IgG (donkey polyclonal)</td><td align="left" valign="bottom">GE Healthcare</td><td align="left" valign="bottom">NA934V<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2722659">AB_2722659</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-Anti-mouse IgG (sheep polyclonal)</td><td align="left" valign="bottom">GE Healthcare</td><td align="left" valign="bottom">NA931V<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_772210">AB_772210</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-B3GALT6 (mouse polyclonal)</td><td align="left" valign="bottom">Bio-Techne</td><td align="left" valign="bottom">H00126792-B01P<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3146818">AB_3146818</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-giantin (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab80864<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10670397">AB_10670397</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 594 anti-rabbit IgG (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A11012<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2534079">AB_2534079</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 anti-mouse IgG (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A21202<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_141607">AB_141607</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 anti-sheep IgG (donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A11015<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2534082">AB_2534082</ext-link></td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 anti-mouse IgG (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A21235<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2535804">AB_2535804</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 anti-rabbit IgG (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A21244<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2535812">AB_2535812</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Silencer SiRNA negative control No 1</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">AM4611</td><td align="left" valign="bottom">50 nM</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human B3GALT6 siRNA</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">Assay ID#112321</td><td align="left" valign="bottom">50 nM</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human B3GALT6 siRNA</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">Assay ID#112322</td><td align="left" valign="bottom">50 nM</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human Laminin-111</td><td align="left" valign="bottom">BioLamina</td><td align="left" valign="bottom">LN111-02</td><td align="left" valign="bottom">5 μg/ml</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human Laminin-411</td><td align="left" valign="bottom">BioLamina</td><td align="left" valign="bottom">LN411-02</td><td align="left" valign="bottom">5 μg/ml</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human Laminin-511</td><td align="left" valign="bottom">BioLamina</td><td align="left" valign="bottom">LN511-0202</td><td align="left" valign="bottom">5 μg/ml</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human IL-1β</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">PHC0813</td><td align="left" valign="bottom">100 ng/ml</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ImmPACT NovaRED peroxidase substrate kit</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">SK4805</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">VECTASTAIN Elite ABC kit</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">PK6100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dimethyl sulfoxide HYBRI-MAX</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">D2650</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Synthetic Mycolactone</td><td align="left" valign="bottom">Prof Yoshito Kishi, Harvard University</td><td align="left" valign="bottom">CAS: 222050-77-3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Biological Mycolactone</td><td align="left" valign="bottom">Dr Estelle Marion, INSERM</td><td align="left" valign="bottom">CAS: 222050-77-3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ipomoeassin F</td><td align="left" valign="bottom">Prof Wei Shi, University of Arkansas</td><td align="left" valign="bottom">CHEMBL4163767</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ZIF-80</td><td align="left" valign="bottom">Prof Wei Shi, University of Arkansas</td><td align="left" valign="bottom">None</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Image J (v1.52n)</td><td align="left" valign="bottom">Fiji</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Zencell-owl software (version 3.3)</td><td align="left" valign="bottom">innoME GmbH</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism Version 9.4.1 and 10.2.3</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ΔG prediction server v1.0</td><td align="left" valign="bottom">dgpred.cbr.su.se</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo v9</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">FlowJo.com</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">JVenn</td><td align="left" valign="bottom">jvenn.toulouse.inrae.fr</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016343">SCR_016343</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Webgestalt</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.webgestalt.org/">https://www.webgestalt.org/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_006786">SCR_006786</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Optimem</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">15392402</td><td align="left" valign="bottom">Serum free medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Escort IV transfection reagent</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">L3287</td><td align="left" valign="bottom">Transfection reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Endothelial cell growth medium 2</td><td align="left" valign="bottom">PromoCell</td><td align="left" valign="bottom">C-22011</td><td align="left" valign="bottom">Culture medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Osteosoft</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">1.01728</td><td align="left" valign="bottom">Decalcifying reagent for histopathology</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Heparinase III (EC4.2.2.8 from <italic>Flavobacterium heparinum</italic>)</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">H8891</td><td align="left" valign="bottom">Enzyme used at 1mU/ml</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Chondroitinase ABC (EC 4.2.2.4 from <italic>Proteus vulgaris</italic>)</td><td align="left" valign="bottom">AMSBIO</td><td align="left" valign="bottom">100330–1 A</td><td align="left" valign="bottom">Enzyme used at 10mU/ml</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Immobilon western chemiluminescence HRP substrate</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">11556345</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">TRITC-conjugated phalloidin</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">FAK100</td><td align="left" valign="bottom">Stain for F-Actin used at 1:500</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">FITC-dextran 70 kDa</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">46945</td><td align="left" valign="bottom">Fluorescently-labelled dextran used for permeability studies used at 1:500</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mycolactone and other translocation inhibitors</title><p>For all experiments in main figure panels, we used synthetic mycolactone A/B (<xref ref-type="bibr" rid="bib55">Song et al., 2002</xref>), which was generously donated by Prof. Yoshito Kishi (Harvard University). However, we also compared synthetic mycolactone A/B to that extracted from cultures of <italic>M. ulcerans</italic> (which also makes mycolactone A/B) which was a kind gift from Dr Estelle Marion (INSERM). Here, <italic>M. ulcerans</italic> 1615 strain, was grown in Middlebrook 7H10 agar supplemented with Oleic Albumin Dextrose Catalase growth supplement. Bacteria were re-suspended in chloroform-methanol (2:1, v/v) and cell debris were removed after centrifugation. Folch extraction was realized by adding 0.2 volume water. The organic phase was dried and phospholipids were precipitated with ice-cold acetone. The acetone-soluble lipids were loaded on a thin layer chromatography plate and eluted with chloroform-methanol-water (90:10:1) solvent as mobile phase. The yellow band with a retention factor of 0.23 was scraped, filtered, evaporated and then resuspended in absolute ethanol. Mycolactone was stored in absolute ethanol at –20 °C in the dark. The amount of purified mycolactone was determined by high-performance liquid chromatography (HPLC) on a C18 column.</p><p>Ipomoeassin F and ZIF-80 (Compound 2 in ref 30) were synthesised by Dr Wei Shi. All synthetic compounds were diluted from stock solutions in DMSO (biological mycolactone stock solution was in ethanol) and were used at the minimal inhibitory concentration, which was 10 ng/ml (~13 nM) mycolactone (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>), 400 nM Ipomoessin F (<xref ref-type="bibr" rid="bib70">Zong et al., 2015</xref>) and 20 nM ZIF-80 (<xref ref-type="bibr" rid="bib72">Zong et al., 2020</xref>). To control for potential impact of the DMSO solvent on cell function, DMSO diluted equivalently was used; typically this was 0.02%.</p></sec><sec id="s4-2"><title>Cell culture and treatment</title><p>Juvenile, single donor human microvascular endothelial cells (HDMEC) and human umbilical vein endothelial cells (HUVEC) (Promocell) were cultured in hVEGF containing Endothelial cell growth medium 2 (Promocell) at 37 °C and 5% CO<sub>2</sub>. Cells were routinely seeded at a concentration of 1x10<sup>4</sup> /cm<sup>2</sup> in 25 cm<sup>2</sup> or 75 cm<sup>2</sup> flasks for no more than 15 population doublings. Where used, laminin-511,–411 or –111 (BioLamina, Sweden) were coated on the surface of uncoated 96-well tissue culture plates at 5 µg/mL in PBS at 4 °C overnight, then washed with medium prior to further experiment. Viability assays used either resazurin dye (Sigma Aldrich) or CellEvent (Invitrogen) as described (<xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Ogbechi et al., 2018</xref>).</p></sec><sec id="s4-3"><title>Uniaxial shear stress induction</title><p>In order to mimic the conditions of flow, we used an established technique using an orbital shaker (<xref ref-type="bibr" rid="bib63">Warboys et al., 2019</xref>). HDMEC were grown to confluency in 6-well plates then placed on an orbital shaker rotating at 150 rpm for 24 hr. Mycolactone or DMSO were added in triplicate and the cells cultured for an additional 48 hr maximum. All phase contrast and fluorescent images were taken towards the edge of the wells, where cells experience uniaxial shear stress (<xref ref-type="bibr" rid="bib63">Warboys et al., 2019</xref>) using an Etaluma Lumascope 620.</p></sec><sec id="s4-4"><title>Time-lapse imaging of live cells</title><p>For time-lapse monitoring, endothelial cells were imaged every 30 min using a zenCELL Owl incubator microscope (innoME GmbH, supplied by LabLogic UK) for 48 hr. Time-lapse videos were generated with zencell-owl software (version 3.3, innoME GmbH), and analysed using their proprietary built-in algorithms of relative cell coverage, proportion of detached cells, and total cell numbers. In some cases, images of cells from certain time points were further analysed in Image J (v1.52n) to cell count of rounded cells per field, and/or the proportion and length/width ratio of elongated cells.</p></sec><sec id="s4-5"><title>Scratch assay</title><p>Endothelial cells were grown to confluency in 24 well plates then single lines were scratched into the monolayer using a p20 pipette tip. Healing of HDMECs was monitored by imaging at various time points up to 24 hr. Each assay was carried out in triplicate wells. Wounded HUVECs were monitored every 15 min by zenCELL Owl microscope (innoME GmbH) for up to 30 hr.</p></sec><sec id="s4-6"><title><italic>Mycobacterium ulcerans</italic> mouse footpad infection model</title><p><italic>Mycobacterium ulcerans</italic> strain Mu_1082 was cultivated on Middlebrook 7H11 agar (Merck) supplemented with 0.2% glycerol (Thermo Fisher Scientific) and 10% OADC (Thermo Fisher Scientific). Several days before inoculation, bacteria were scraped from the plate and resuspended in 10 ml 7H9 medium (Becton Dickinson) containing 0.5% glycerol, 10% OADC and 0.2% Tween-80 (Merck) and incubated shaking with 3 µm glass beads for 3 days at 31 °C. To prepare the inoculum, cultures were allowed to stand for 10 min (to allow clumps to settle) then 1 ml culture was centrifuged at 13,000 x <italic>g</italic> for 2 min. The supernatant was removed, and the pellet resuspended in Dulbecco’s PBS (Thermo Fisher Scientific). After measuring the OD600, 3.33x10<sup>7</sup> bacteria were pelleted and resuspended in 10 ml PBS, to give an inoculum of ~10<sup>5</sup> cfu/footpad in a volume of 30 µl.</p><p>All in vivo procedures were approved by the University of Surrey’s AWERB and UK Home office and met relevant animal welfare and biosafety regulatory standards (under PPL PP0344017). ARRIVE guidelines were followed, and the ARRIVE checklist is provided. In this publication we present new histological analysis of archived material from 8 to 9-week-old wild type C57BL/6J female mice (Charles River, UK), which had been inoculated intradermally with 30 μl of the bacterial suspension or vehicle control (PBS) to the left hind footpad, under gas anaesthesia. Mice were maintained under specific pathogen-free conditions at a temperature of 20–24 °C and humidity of 45 to 65% in individually HEPA filtered cages. The mice were acclimatised for &gt;1 week before being transferred into the CL3, where they acclimatised for at least a further 48 hours before infection. They had free access to water and a standard balanced diet, standard bedding and enrichments including a tunnel and nesting material. Infected mice were housed separately from uninfected mice and blinding was not possible as the infection is clearly visible. Infection grade was assessed daily according to the method of Converse (<xref ref-type="bibr" rid="bib9">Converse et al., 2011</xref>), where Grade 1 showed swelling of the metatarsal area (&lt;50% increase compared to normal), Grade 2 showed greater swelling (50-150%) and Grade 3 had swelling further up the leg, visualised at the hock. No mice were excluded, experienced adverse events, or reached the humane endpoint (based on infection score, mobility, weight, and assessment of pain and secondary infection; or oedema extending into the “thigh” area and/or bedding adhering to the footpad suggesting footpad ulceration) in these experiments. Mice were killed by a schedule 1 method (cervical dislocation). The whole foot was then removed and fixed by immersion in 10% neutral buffered formalin for at least 24 hr.</p></sec><sec id="s4-7"><title>Histological analysis of murine foot samples</title><p>Fixed murine feet were decalcified using the EDTA-based Osteosoft solution (Merck) and then embedded in paraffin for histological analysis by Ziehl-Neelsen stain, Alcian blue-periodic acid Schiff stain, and immunohistochemistry (IHC) for fibrin(ogen). For IHC staining, 5 μm tissue sections on polylysine-coated slides were deparaffinised, endogenous peroxidase quenched, epitope unmasked with heated IHC citrate buffer (pH 6.0) (Merck) and blocked with 5% bovine serum albumin. The tissue sections were incubated with anti-fibrinogen antibody (A0080, DAKO) or matched isotype control overnight at 4 °C. Staining was then performed with biotinylated horse anti-rabbit IgG (Vector Laboratories) and VECTASTAIN Elite ABC kit and ImmPACT NovaRED peroxidase substrate and further counterstained with Harris Haematoxylin (ThermoFisher Scientific). Whole slide images were captured using the NanoZoomer slide scanner (Hamamatsu Photonics) and analysed using ImageScope software (Leica Biosystems) and ndp2.view software (Hamamatsu). Some photographs were taken with Micropix microscope camera (acquisition software Cytocam) attached to a Yenway CX40 laboratory microscope (Micropix).</p></sec><sec id="s4-8"><title>Electron microscopy</title><p>Glabrous skin from the infected hind paw of a mouse at grade 1 was dissected and freshly immersed in a fixative solution containing 4% Formaldehyde and 3% Glutaraldehyde. After 24 hr, the tissue area of interest was chosen via examination of semi-thin sections of 500 nm stained with toluidine blue. By using a Leica ultramicrotome with diamond knife, ultrathin sections of 100 nm were collected into copper grids and images were obtained by FEI Tecnai T12.</p></sec><sec id="s4-9"><title>Membrane protein preparation</title><p>HDMEC (1x10<sup>7</sup> cells) were seeded onto 15 cm dishes (Corning) and grown to 90% confluency then exposed to solvent carrier DMSO or 10 ng/ml mycolactone for 24 hr. Cells were washed four times in PBS and once in lysis buffer (10 mM Tris pH 7.5, 250 mM Sucrose, protease inhibitor cocktail). Cells were incubated for 20 min on ice in 10 ml lysis buffer then lysed in by 20 strokes dounce homogenisation. Lysates were centrifuged at 1000x<italic>g</italic> for 10 min at 4 °C then the post-nuclear supernatant was centrifuged at 100,000x<italic>g</italic> for 1 hr at 4 °C. Pellets were resuspended in 110 µl lysis buffer. Protein concentration was determined by BCA assay and 50 µg aliquots were subjected to acetone precipitation. Triplicate samples were prepared from three independent assays.</p></sec><sec id="s4-10"><title>Proteomics</title><p>Acetone precipitated proteins were reduced, alkylated and digested with trypsin before 9-plex isobaric TMT labelling according to the <ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FLSG%2Fmanuals%2FMAN0016969_2162457_TMT10plex_UG.pdf">manufacturer’s protocol</ext-link>. Labelled peptides were separated by high pH reverse phase liquid chromatography, collecting 20 fractions which were then lyophilised, desalted and analysed by LC-MS/MS. TMT labelled samples were analysed by the SPS-MP3 method using an Orbitrap Lumos mass spectrometer. Spectra were searched using the Mascot search engine version (Matrix Science) and analysed using the Proteome Discovery platform. (Version 2.2 Thermo Fisher Scientific). NA values and low confidence proteins were removed, and data was normalised using each channel median. Differential expression analysis was carried out using Limma. Adjusted p values were calculated by the Benjamini-Hochberg method. UniProt and the Human Protein Atlas (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</ext-link>) were used to determine protein location and characteristics. Over-representation of GO groups was assessed using Webgestalt (<ext-link ext-link-type="uri" xlink:href="https://www.webgestalt.org/">https://www.webgestalt.org/</ext-link>) (ref). Signal peptide ΔG values were obtained via the ΔG Prediction Server V1.0 (<ext-link ext-link-type="uri" xlink:href="https://dgpred.cbr.su.se">https://dgpred.cbr.su.se</ext-link>). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (<xref ref-type="bibr" rid="bib47">Perez-Riverol et al., 2022</xref>) partner repository with the dataset identifier PXD037489.</p></sec><sec id="s4-11"><title>siRNA transfection</title><p>HUVECs (2x10<sup>5</sup> cells) were seeded onto a six-well plate. The next day, cells were washed with Opti-MEM (Gibco) and then kept in 1 ml medium. Each siRNA (Silencer siRNA assays ID#112321, #112322 for B3GALT6 or Silencer negative control No.1 siRNA AM4611; Invitrogen ThermoFisher Scientific) was diluted in Opti-MEM to 0.6 μM, mixed with equal volume of diluted Escort IV transfection reagent (L3287, Merck; final concentration 60 μg/mL). The transfection was performed onto HUVECs with ~40% confluency. Medium was changed back to normal endothelial culture medium 5 hr later. The transfectants received treatment 24 hr post transfection and were subjected to the respective analysis (e.g. image, sample harvest for immunochemical assays) after another 24 hr.</p></sec><sec id="s4-12"><title>Flow cytometry</title><p>Flow cytometry was carried out according to standard methods as described in <xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref> using an Attune NxT flow cytometer (ThermoFisher Scientific). Cells were detached with non-enzymatic cell dissociation solution (Merck) or briefly (for Itgb4 staining only) trypsinised with 0.04% trypsin/ 0.03% EDTA (PromoCell). For surface GAG detection, cells were treated with 1mU of heparinase III (EC4.2.2.8 from <italic>Flavobacterium heparinum</italic>) to expose the neo-epitope of heparan sulphate or with chondroitinase ABC (EC 4.2.2.4 from <italic>Proteus vulgaris</italic>) (AMS Biotechnology) for 1 hr at 37 °C prior to the staining procedures. Antibodies were Δ-HS (F69-3G10, AMS Biotechnology), CS (CS56, Merck), HSPG2/perlecan (7B5, ThermoFisher Scientific), glypican-1 (AF4519), integrin β4/CD104 (clone 439-9B, eBioscience), integrin β1/CD29 (P4C10, NBP2-36561), syndecan-2 (MAB2965), biglycan (AF2667), laminin α5 (NBP2-42391) from Biotechne. Isotype control mouse IgG1 (P3.6.2.8.1; 14-4714-81 from Invitrogen), mouse IgG2b (MG2B00), goat IgG (AB-108-C from R&amp;D), rat IgG2b (14-4031-81), mouse IgM (PFR-03) and fluorophore-conjugated secondary antibodies goat anti-mouse IgG PE (12-4010-82), donkey anti-goat IgG FITC (A16000), and anti-rat IgG FITC (31629) were from ThermoFisher Scientific. The main population was gated by forward and side scatter plot of untreated cells using FlowJo (v9); among this, single cell population of 10<sup>4</sup> cells per condition was subjected to analysis. Mean fluorescence intensity was determined and presented as % relative to untreated control.</p></sec><sec id="s4-13"><title>Immunoblotting</title><p>Immunoblotting was carried out according to standard methods as described in <xref ref-type="bibr" rid="bib41">Ogbechi et al., 2015</xref>. Endothelial cells were lysed either in RIPA buffer (where protein content-equalised post-nuclear fractions were used) or directly in ‘gel sample buffer’ (with sonication to degrade genomic DNA). Immunoblotting of commercial pre-cast gels (BioRad) used either Immobilon PVDF membranes (Merck) or nitrocellulose membranes (GE Healthcare). Antibodies used in this study were: Δ-HS (F69-3G10, AMS Biotechnology); anti-fibronectin (AB1945, Merck); anti-integrin α5 (sc-166665); anti-rabbit-HRP (GE Healthcare, NA934V), anti-mouse-HRP (GE Healthcare, NA931V). To visualise the HS neoepitope, protein lysate was digested with 1 mU of heparinase III (EC4.2.2.8 from <italic>Flavobacterium heparinum</italic>) prior to SDS-PAGE. Blots were developed using enhanced chemiluminescence with Immobilon western chemiluminescence HRP substrate (Thermo Fisher Scientific, 11556345) and imaged on a Fusion FX Imager (Vilber-Lourmatclean), which provides a warning if the areas of the image are saturated.</p></sec><sec id="s4-14"><title>Immunofluorescence</title><p>Immunofluorescent imaging was carried out according to standard methods as described in <xref ref-type="bibr" rid="bib26">Hall et al., 2022</xref>. Cells were fixed with 4% paraformaldehyde in PBS. For visualising intracellular markers, cells were permeabilised wit 0.25% Nonidet P-40 alternative in NETGEL buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris-Cl, pH 7.4, 0.05% Nonidet P-40 alternative, 0.25% gelatin and 0.02% sodium azide). Antibodies used in this study were: B3GALT6 (H00126792-B01P, Biotechne)<italic>,</italic> GOLGB1<italic>/</italic>Giantin (ab80864, abcam), Laminin α4 (AF7340, Biotechne), Δ-HS (F69-3G10, AMS Biotechnology), HSPG2/perlecan (7B5, Thermo Fisher Scientific), TRITC-conjugated phalloidin (FAK100, Merck), Alexa Fluor 594 goat anti-rabbit (A11012), Alexa Fluor 488 donkey anti-mouse (A21202) and Alexa Fluor 488 donkey anti-sheep (A11015) from Invitrogen/Thermo Fisher Scientific. For B3GALT6 intensity in the Golgi apparatus, the region of interest per cell was defined by giantin-positive staining using ImageJ selection tools. The integrated density of B3GALT6 fluorescence of selected regions and background reading were then measured and the difference between the two numbers were corrected total cell fluorescence.</p></sec><sec id="s4-15"><title>Vascular permeability assay</title><p>Endothelial cells were seeded on hanging cell culture inserts containing 1 µm pores with a polyethylene terephthalate membrane (Falcon). Treatment as above or with 100 ng/mL IL-1β (Gibco) were applied to both the insert and receiver wells. After indicated time, fluorescein isothiocyanate (FITC)-conjugated dextran (70 kDa, Millipore) was applied to each insert for 20 min. The fluorescence intensity of the solution in the receiver wells was then assessed by a fluorescent plate reader (FLUOstar Omega, BMG Labtech) with excitation/ emission wavelength at 485/530 nm. Fluorescence intensity was normalised to untreated control wells with an intact monolayer of endothelial cells and expressed as a % of subtracted value obtained from wells where no cells were seeded to the insert.</p></sec><sec id="s4-16"><title>Adhesion assay</title><p>HDMECs were harvested, incubated with anti-integrin β1 (clone P4C10, NBP2-36561, Biotechne) or isotype control mouse IgG1 (P3.6.2.8.1; 14-4714-81 from Invitrogen) for 5 min, then 1.5x10<sup>4</sup> cells were added to the wells of a 96-well plate that had been coated or not with different laminins as described above. After 1 hr, each well was washed three times with serum free medium and attached cells were imaged with a digital microscope camera (Micropix) attached to an AE31E inverted microscope (Motic). The cell count per image was determined using ImageJ.</p></sec><sec id="s4-17"><title>Statistical analysis</title><p>All data, with exception of the live-cell imaging using the ZenCell OWL (see above), were analysed using GraphPad Prism Version 9.4.1 and 10.2.3. Data were analysed using a one- or two-way ANOVA using an appropriate correction for multiple comparisons (either Dunnett’s, or Tukey’s). Some two-way ANOVAs also included the Geisser Greenhouse correction for sphericity.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Writing – original draft</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Visualization, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All in vivo procedures were approved by the University of Surrey's AWERB and UK Home office and met relevant animal welfare and biosafety regulatory standards (under PPL PP0344017). Animals were housed in cages with environmental enrichments in a unit with a strong culture of care. Animals were infected under gas anaesthesia. ARRIVE guidelines were followed, and the ARRIVE checklist is provided.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-86931-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD037489. Figure 1—source data 1, Figure 4—source data 1, Figure 5—source data 1, Figure 6—source data 1, Figure 7—source data 1, and Figure 8—source data 1 contain the numerical data used to generate graphs.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Umrania</surname><given-names>Y</given-names></name><name><surname>Deery</surname><given-names>MJ</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Mycolactone causes destructive Sec61-dependent loss of the endothelial glycocalyx and basement membrane: a new indirect mechanism driving tissue necrosis in Mycobacterium ulcerans infection</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="http://www.ebi.ac.uk/pride/archive/projects/PXD037489">PXD037489</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are extremely grateful to Prof Yoshito Kishi (Harvard University, USA) for the gift of synthetic mycolactone A/B. We dedicate this paper to the memory of this tremendous scientist who did some much to advance research into the pathogenesis of Buruli ulcer. We thank Dr Estelle Marion (Inserm U1302 INCIT, Angers, France) for the biologically purified mycolactone, and Prof Richard Phillips (Kumasi Centre for Collaborative Research in Tropical Medicine) who provided the <italic>M ulcerans</italic> strain used in this work. We thank Katherine Walker and Ella May of the University of Surrey’s Veterinary Pathology Centre for their assistance with tissue processing and staining of murine samples, and Dr Paola Campagnola (University of Surrey) for her advice in setting up the endothelial cells under flow. This work is supported by a Wellcome Trust Investigator Award in Science to Prof Rachel Simmonds (WT202843/Z/16/Z). Chemical synthesis of Ipomoeassin F and ZIF-80 was supported by an AREA grant GM116032 from the National Institute of General Medical Sciences of the National Institutes of Health (NIH) to Prof Wei Q Shi.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardou</surname><given-names>P</given-names></name><name><surname>Mariette</surname><given-names>J</given-names></name><name><surname>Escudié</surname><given-names>F</given-names></name><name><surname>Djemiel</surname><given-names>C</given-names></name><name><surname>Klopp</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>jvenn: an interactive Venn diagram viewer</article-title><source>BMC Bioinformatics</source><volume>15</volume><elocation-id>293</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-15-293</pub-id><pub-id pub-id-type="pmid">25176396</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>TH</given-names></name><name><surname>Engler</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The provisional matrix: setting the stage for tissue repair outcomes</article-title><source>Matrix Biology</source><volume>60–61</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2017.04.003</pub-id><pub-id pub-id-type="pmid">28527902</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>L</given-names></name><name><surname>Paatero</surname><given-names>AO</given-names></name><name><surname>Morel</surname><given-names>J-D</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name><name><surname>Guenin-Macé</surname><given-names>L</given-names></name><name><surname>Saint-Auret</surname><given-names>S</given-names></name><name><surname>Blanchard</surname><given-names>N</given-names></name><name><surname>Dillmann</surname><given-names>R</given-names></name><name><surname>Niang</surname><given-names>F</given-names></name><name><surname>Pellegrini</surname><given-names>S</given-names></name><name><surname>Taunton</surname><given-names>J</given-names></name><name><surname>Paavilainen</surname><given-names>VO</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mycolactone subverts immunity by selectively blocking the Sec61 translocon</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>2885</fpage><lpage>2896</lpage><pub-id pub-id-type="doi">10.1084/jem.20160662</pub-id><pub-id pub-id-type="pmid">27821549</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieri</surname><given-names>R</given-names></name><name><surname>Scherr</surname><given-names>N</given-names></name><name><surname>Ruf</surname><given-names>M-T</given-names></name><name><surname>Dangy</surname><given-names>J-P</given-names></name><name><surname>Gersbach</surname><given-names>P</given-names></name><name><surname>Gehringer</surname><given-names>M</given-names></name><name><surname>Altmann</surname><given-names>K-H</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The macrolide toxin mycolactone promotes bim-dependent apoptosis in buruli ulcer through inhibition of mTOR</article-title><source>ACS Chemical Biology</source><volume>12</volume><fpage>1297</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00053</pub-id><pub-id pub-id-type="pmid">28294596</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butenas</surname><given-names>S</given-names></name><name><surname>Orfeo</surname><given-names>T</given-names></name><name><surname>Mann</surname><given-names>KG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tissue factor in coagulation: which? where? when?</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>29</volume><fpage>1989</fpage><lpage>1996</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.177402</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>H-M</given-names></name><name><surname>Chiou</surname><given-names>W-Y</given-names></name><name><surname>Hsu</surname><given-names>W-J</given-names></name><name><surname>Wu</surname><given-names>L-H</given-names></name><name><surname>Yang</surname><given-names>M-H</given-names></name><name><surname>Tyan</surname><given-names>Y-C</given-names></name><name><surname>Lee</surname><given-names>C-H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title><italic>Salmonella</italic> alters heparanase expression and reduces tumor metastasis</article-title><source>International Journal of Medical Sciences</source><volume>18</volume><fpage>2981</fpage><lpage>2989</lpage><pub-id pub-id-type="doi">10.7150/ijms.60281</pub-id><pub-id pub-id-type="pmid">34220326</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Lanigan</surname><given-names>JM</given-names></name><name><surname>DellaPelle</surname><given-names>P</given-names></name><name><surname>Manseau</surname><given-names>E</given-names></name><name><surname>Dvorak</surname><given-names>HF</given-names></name><name><surname>Colvin</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization</article-title><source>The Journal of Investigative Dermatology</source><volume>79</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12500075</pub-id><pub-id pub-id-type="pmid">6752288</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colman</surname><given-names>M</given-names></name><name><surname>Van Damme</surname><given-names>T</given-names></name><name><surname>Steichen-Gersdorf</surname><given-names>E</given-names></name><name><surname>Laccone</surname><given-names>F</given-names></name><name><surname>Nampoothiri</surname><given-names>S</given-names></name><name><surname>Syx</surname><given-names>D</given-names></name><name><surname>Guillemyn</surname><given-names>B</given-names></name><name><surname>Symoens</surname><given-names>S</given-names></name><name><surname>Malfait</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The clinical and mutational spectrum of B3GAT3 linkeropathy: two case reports and literature review</article-title><source>Orphanet Journal of Rare Diseases</source><volume>14</volume><elocation-id>138</elocation-id><pub-id pub-id-type="doi">10.1186/s13023-019-1110-9</pub-id><pub-id pub-id-type="pmid">31196143</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Converse</surname><given-names>PJ</given-names></name><name><surname>Nuermberger</surname><given-names>EL</given-names></name><name><surname>Almeida</surname><given-names>DV</given-names></name><name><surname>Grosset</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?</article-title><source>Future Microbiology</source><volume>6</volume><fpage>1185</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.2217/fmb.11.101</pub-id><pub-id pub-id-type="pmid">22004037</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottam</surname><given-names>DW</given-names></name><name><surname>Corbitt</surname><given-names>RH</given-names></name><name><surname>Gomez</surname><given-names>DE</given-names></name><name><surname>Rees</surname><given-names>RC</given-names></name><name><surname>Thorgeirsson</surname><given-names>UP</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium</article-title><source>Journal of Cellular Biochemistry</source><volume>60</volume><fpage>148</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1002/(sici)1097-4644(19960101)60:13.0.co;2-l</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>GE</given-names></name><name><surname>Senger</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization</article-title><source>Circulation Research</source><volume>97</volume><fpage>1093</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000191547.64391.e3</pub-id><pub-id pub-id-type="pmid">16306453</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demangel</surname><given-names>C</given-names></name><name><surname>High</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sec61 blockade by mycolactone: a central mechanism in Buruli ulcer disease</article-title><source>Biology of the Cell</source><volume>110</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1111/boc.201800030</pub-id><pub-id pub-id-type="pmid">30055020</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Russo</surname><given-names>J</given-names></name><name><surname>Luik</surname><given-names>A-L</given-names></name><name><surname>Yousif</surname><given-names>L</given-names></name><name><surname>Budny</surname><given-names>S</given-names></name><name><surname>Oberleithner</surname><given-names>H</given-names></name><name><surname>Hofschröer</surname><given-names>V</given-names></name><name><surname>Klingauf</surname><given-names>J</given-names></name><name><surname>van Bavel</surname><given-names>E</given-names></name><name><surname>Bakker</surname><given-names>EN</given-names></name><name><surname>Hellstrand</surname><given-names>P</given-names></name><name><surname>Bhattachariya</surname><given-names>A</given-names></name><name><surname>Albinsson</surname><given-names>S</given-names></name><name><surname>Pincet</surname><given-names>F</given-names></name><name><surname>Hallmann</surname><given-names>R</given-names></name><name><surname>Sorokin</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial basement membrane laminin 511 is essential for shear stress response</article-title><source>The EMBO Journal</source><volume>36</volume><fpage>183</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.15252/embj.201694756</pub-id><pub-id pub-id-type="pmid">27940654</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Förster</surname><given-names>B</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name><name><surname>Thye</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mycolactone induces cell death by SETD1B-dependent degradation of glutathione</article-title><source>PLOS Neglected Tropical Diseases</source><volume>14</volume><elocation-id>e0008709</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0008709</pub-id><pub-id pub-id-type="pmid">33006969</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulon</surname><given-names>M</given-names></name><name><surname>Robbe-Saule</surname><given-names>M</given-names></name><name><surname>Manry</surname><given-names>J</given-names></name><name><surname>Esnault</surname><given-names>L</given-names></name><name><surname>Boucaud</surname><given-names>Y</given-names></name><name><surname>Alcaïs</surname><given-names>A</given-names></name><name><surname>Malloci</surname><given-names>M</given-names></name><name><surname>Fanton d’Andon</surname><given-names>M</given-names></name><name><surname>Beauvais</surname><given-names>T</given-names></name><name><surname>Labarriere</surname><given-names>N</given-names></name><name><surname>Jeannin</surname><given-names>P</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Saint-André</surname><given-names>JP</given-names></name><name><surname>Croué</surname><given-names>A</given-names></name><name><surname>Delneste</surname><given-names>Y</given-names></name><name><surname>Boneca</surname><given-names>IG</given-names></name><name><surname>Marsollier</surname><given-names>L</given-names></name><name><surname>Marion</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1009107</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009107</pub-id><pub-id pub-id-type="pmid">33338061</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gama</surname><given-names>JB</given-names></name><name><surname>Ohlmeier</surname><given-names>S</given-names></name><name><surname>Martins</surname><given-names>TG</given-names></name><name><surname>Fraga</surname><given-names>AG</given-names></name><name><surname>Sampaio-Marques</surname><given-names>B</given-names></name><name><surname>Carvalho</surname><given-names>MA</given-names></name><name><surname>Proença</surname><given-names>F</given-names></name><name><surname>Silva</surname><given-names>MT</given-names></name><name><surname>Pedrosa</surname><given-names>J</given-names></name><name><surname>Ludovico</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteomic analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen</article-title><source>PLOS Neglected Tropical Diseases</source><volume>8</volume><elocation-id>e3066</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003066</pub-id><pub-id pub-id-type="pmid">25101965</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>KM</given-names></name><name><surname>Chatterjee</surname><given-names>D</given-names></name><name><surname>Gunawardana</surname><given-names>G</given-names></name><name><surname>Welty</surname><given-names>D</given-names></name><name><surname>Hayman</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Small</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence</article-title><source>Science</source><volume>283</volume><fpage>854</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1126/science.283.5403.854</pub-id><pub-id pub-id-type="pmid">9933171</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gérard</surname><given-names>SF</given-names></name><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Zaki</surname><given-names>AM</given-names></name><name><surname>Corfield</surname><given-names>KA</given-names></name><name><surname>Mayerhofer</surname><given-names>PU</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>Whelligan</surname><given-names>DK</given-names></name><name><surname>Biggin</surname><given-names>PC</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name><name><surname>Higgins</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of the inhibited state of the sec translocon</article-title><source>Molecular Cell</source><volume>79</volume><fpage>406</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.013</pub-id><pub-id pub-id-type="pmid">32692975</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grönberg</surname><given-names>A</given-names></name><name><surname>Zettergren</surname><given-names>L</given-names></name><name><surname>Bergh</surname><given-names>K</given-names></name><name><surname>Ståhle</surname><given-names>M</given-names></name><name><surname>Heilborn</surname><given-names>J</given-names></name><name><surname>Angeby</surname><given-names>K</given-names></name><name><surname>Small</surname><given-names>PL</given-names></name><name><surname>Akuffo</surname><given-names>H</given-names></name><name><surname>Britton</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Antioxidants protect keratinocytes against <italic>M. ulcerans</italic> mycolactone cytotoxicity</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13839</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013839</pub-id><pub-id pub-id-type="pmid">21079804</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotzke</surname><given-names>JE</given-names></name><name><surname>Kozik</surname><given-names>P</given-names></name><name><surname>Morel</surname><given-names>J-D</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name><name><surname>Pietrosemoli</surname><given-names>N</given-names></name><name><surname>Cresswell</surname><given-names>P</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export</article-title><source>PNAS</source><volume>114</volume><fpage>E5910</fpage><lpage>E5919</lpage><pub-id pub-id-type="doi">10.1073/pnas.1705242114</pub-id><pub-id pub-id-type="pmid">28679634</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenin-Macé</surname><given-names>L</given-names></name><name><surname>Carrette</surname><given-names>F</given-names></name><name><surname>Asperti-Boursin</surname><given-names>F</given-names></name><name><surname>Le Bon</surname><given-names>A</given-names></name><name><surname>Caleechurn</surname><given-names>L</given-names></name><name><surname>Di Bartolo</surname><given-names>V</given-names></name><name><surname>Fontanet</surname><given-names>A</given-names></name><name><surname>Bismuth</surname><given-names>G</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression</article-title><source>PNAS</source><volume>108</volume><fpage>12833</fpage><lpage>12838</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016496108</pub-id><pub-id pub-id-type="pmid">21768364</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenin-Macé</surname><given-names>L</given-names></name><name><surname>Veyron-Churlet</surname><given-names>R</given-names></name><name><surname>Thoulouze</surname><given-names>M-I</given-names></name><name><surname>Romet-Lemonne</surname><given-names>G</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Leadlay</surname><given-names>PF</given-names></name><name><surname>Danckaert</surname><given-names>A</given-names></name><name><surname>Ruf</surname><given-names>M-T</given-names></name><name><surname>Mostowy</surname><given-names>S</given-names></name><name><surname>Zurzolo</surname><given-names>C</given-names></name><name><surname>Bousso</surname><given-names>P</given-names></name><name><surname>Chrétien</surname><given-names>F</given-names></name><name><surname>Carlier</surname><given-names>M-F</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>1501</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1172/JCI66576</pub-id><pub-id pub-id-type="pmid">23549080</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>E</given-names></name><name><surname>Almonte-Becerril</surname><given-names>M</given-names></name><name><surname>Bloch</surname><given-names>W</given-names></name><name><surname>Costell</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Perlecan maintains microvessel integrity in vivo and modulates their formation in vitro</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e53715</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053715</pub-id><pub-id pub-id-type="pmid">23320101</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Hill</surname><given-names>K</given-names></name><name><surname>McKenna</surname><given-names>M</given-names></name><name><surname>Ogbechi</surname><given-names>J</given-names></name><name><surname>High</surname><given-names>S</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004061</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004061</pub-id><pub-id pub-id-type="pmid">24699819</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Hsieh</surname><given-names>LT-H</given-names></name><name><surname>Sacre</surname><given-names>S</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The one that got away: how macrophage-derived IL-1β Escapes the mycolactone-dependent sec61 blockade in buruli ulcer</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>788146</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.788146</pub-id><pub-id pub-id-type="pmid">35154073</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Dos Santos</surname><given-names>SJ</given-names></name><name><surname>Hsieh</surname><given-names>LTH</given-names></name><name><surname>Manifava</surname><given-names>M</given-names></name><name><surname>Ruf</surname><given-names>MT</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name><name><surname>Ktistakis</surname><given-names>N</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inhibition of the SEC61 translocon by mycolactone induces a protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity</article-title><source>Autophagy</source><volume>18</volume><fpage>841</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1080/15548627.2021.1961067</pub-id><pub-id pub-id-type="pmid">34424124</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>IC</given-names></name><name><surname>Mitra</surname><given-names>R</given-names></name><name><surname>Mensah</surname><given-names>SA</given-names></name><name><surname>Nersesyan</surname><given-names>A</given-names></name><name><surname>Bal</surname><given-names>NN</given-names></name><name><surname>Ebong</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endothelial barrier reinforcement relies on flow-regulated glycocalyx, a potential therapeutic target</article-title><source>Biorheology</source><volume>56</volume><fpage>131</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.3233/BIR-180205</pub-id><pub-id pub-id-type="pmid">30988234</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>LT-H</given-names></name><name><surname>Dos Santos</surname><given-names>SJ</given-names></name><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Ogbechi</surname><given-names>J</given-names></name><name><surname>Loglo</surname><given-names>AD</given-names></name><name><surname>Salguero</surname><given-names>FJ</given-names></name><name><surname>Ruf</surname><given-names>M-T</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1010280</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010280</pub-id><pub-id pub-id-type="pmid">35100311</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>V</given-names></name><name><surname>Troughton</surname><given-names>LD</given-names></name><name><surname>Hamill</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Laminins: roles and utility in wound repair</article-title><source>Advances in Wound Care</source><volume>4</volume><fpage>250</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1089/wound.2014.0533</pub-id><pub-id pub-id-type="pmid">25945287</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>J</given-names></name><name><surname>Ishihara</surname><given-names>A</given-names></name><name><surname>Fukunaga</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>MJV</given-names></name><name><surname>Briquez</surname><given-names>PS</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2163</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04525-w</pub-id><pub-id pub-id-type="pmid">29867149</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikegawa</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Nambu</surname><given-names>R</given-names></name><name><surname>Etchuya</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Mukai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Signal-anchor sequences are an essential factor for the Golgi-plasma membrane localization of type II membrane proteins</article-title><source>Bioscience, Biotechnology, and Biochemistry</source><volume>82</volume><fpage>1708</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1080/09168451.2018.1484272</pub-id><pub-id pub-id-type="pmid">29912671</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwaffo</surname><given-names>YA</given-names></name><name><surname>Sarpong-Duah</surname><given-names>M</given-names></name><name><surname>Owusu-Boateng</surname><given-names>K</given-names></name><name><surname>Gbewonyo</surname><given-names>WS</given-names></name><name><surname>Adjimani</surname><given-names>JP</given-names></name><name><surname>Mosi</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Natural antioxidants attenuate mycolactone toxicity to RAW 264.7 macrophages</article-title><source>Experimental Biology and Medicine</source><volume>246</volume><fpage>1884</fpage><lpage>1894</lpage><pub-id pub-id-type="doi">10.1177/15353702211015628</pub-id><pub-id pub-id-type="pmid">34038223</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfait</surname><given-names>F</given-names></name><name><surname>Kariminejad</surname><given-names>A</given-names></name><name><surname>Van Damme</surname><given-names>T</given-names></name><name><surname>Gauche</surname><given-names>C</given-names></name><name><surname>Syx</surname><given-names>D</given-names></name><name><surname>Merhi-Soussi</surname><given-names>F</given-names></name><name><surname>Gulberti</surname><given-names>S</given-names></name><name><surname>Symoens</surname><given-names>S</given-names></name><name><surname>Vanhauwaert</surname><given-names>S</given-names></name><name><surname>Willaert</surname><given-names>A</given-names></name><name><surname>Bozorgmehr</surname><given-names>B</given-names></name><name><surname>Kariminejad</surname><given-names>MH</given-names></name><name><surname>Ebrahimiadib</surname><given-names>N</given-names></name><name><surname>Hausser</surname><given-names>I</given-names></name><name><surname>Huysseune</surname><given-names>A</given-names></name><name><surname>Fournel-Gigleux</surname><given-names>S</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Defective initiation of glycosaminoglycan synthesis due to B3GALT6 mutations causes a pleiotropic Ehlers-Danlos-syndrome-like connective tissue disorder</article-title><source>American Journal of Human Genetics</source><volume>92</volume><fpage>935</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2013.04.016</pub-id><pub-id pub-id-type="pmid">23664118</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>M</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name><name><surname>High</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanistic insights into the inhibition of Sec61-dependent co- and post-translational translocation by mycolactone</article-title><source>Journal of Cell Science</source><volume>129</volume><fpage>1404</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1242/jcs.182352</pub-id><pub-id pub-id-type="pmid">26869228</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>M</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name><name><surname>High</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>1307</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1242/jcs.198655</pub-id><pub-id pub-id-type="pmid">28219954</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihalic Mosher</surname><given-names>T</given-names></name><name><surname>Zygmunt</surname><given-names>DA</given-names></name><name><surname>Koboldt</surname><given-names>DC</given-names></name><name><surname>Kelly</surname><given-names>BJ</given-names></name><name><surname>Johnson</surname><given-names>LR</given-names></name><name><surname>McKenna</surname><given-names>DS</given-names></name><name><surname>Hood</surname><given-names>BC</given-names></name><name><surname>Hickey</surname><given-names>SE</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Martin</surname><given-names>PT</given-names></name><name><surname>McBride</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Expansion of B4GALT7 linkeropathy phenotype to include perinatal lethal skeletal dysplasia</article-title><source>European Journal of Human Genetics</source><volume>27</volume><fpage>1569</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1038/s41431-019-0464-8</pub-id><pub-id pub-id-type="pmid">31278392</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname><given-names>JH</given-names></name><name><surname>Cunningham</surname><given-names>J</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Roles for laminin in embryogenesis: exencephaly, syndactyly, and placentopathy in mice lacking the laminin alpha5 chain</article-title><source>The Journal of Cell Biology</source><volume>143</volume><fpage>1713</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1083/jcb.143.6.1713</pub-id><pub-id pub-id-type="pmid">9852162</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morel</surname><given-names>J-D</given-names></name><name><surname>Paatero</surname><given-names>AO</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Guenin-Macé</surname><given-names>L</given-names></name><name><surname>Van Haver</surname><given-names>D</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name><name><surname>Pietrosemoli</surname><given-names>N</given-names></name><name><surname>Paavilainen</surname><given-names>VO</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Proteomics reveals scope of mycolactone-mediated sec61 blockade and distinctive stress signature</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>17</volume><fpage>1750</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA118.000824</pub-id><pub-id pub-id-type="pmid">29915147</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Stutz</surname><given-names>R</given-names></name><name><surname>Schorr</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Pfeffer</surname><given-names>S</given-names></name><name><surname>Freeze</surname><given-names>HH</given-names></name><name><surname>Förster</surname><given-names>F</given-names></name><name><surname>Helms</surname><given-names>V</given-names></name><name><surname>Dudek</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Proteomics reveals signal peptide features determining the client specificity in human TRAP-dependent ER protein import</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3765</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06188-z</pub-id><pub-id pub-id-type="pmid">30217974</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicosia</surname><given-names>RF</given-names></name><name><surname>Bonanno</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Fibronectin promotes the elongation of microvessels during angiogenesis in vitro</article-title><source>Journal of Cellular Physiology</source><volume>154</volume><fpage>654</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1002/jcp.1041540325</pub-id><pub-id pub-id-type="pmid">7679680</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogbechi</surname><given-names>J</given-names></name><name><surname>Ruf</surname><given-names>MT</given-names></name><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Bodman-Smith</surname><given-names>K</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>HL</given-names></name><name><surname>Stainer</surname><given-names>A</given-names></name><name><surname>Esmon</surname><given-names>CT</given-names></name><name><surname>Ahnström</surname><given-names>J</given-names></name><name><surname>Pluschke</surname><given-names>G</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mycolactone-dependent depletion of endothelial cell thrombomodulin is strongly associated with fibrin deposition in buruli ulcer lesions</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1005011</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005011</pub-id><pub-id pub-id-type="pmid">26181660</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogbechi</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Sbarrato</surname><given-names>T</given-names></name><name><surname>Taunton</surname><given-names>J</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name><name><surname>Wek</surname><given-names>RC</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>397</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0427-y</pub-id><pub-id pub-id-type="pmid">29540678</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Keefe</surname><given-names>S</given-names></name><name><surname>Zong</surname><given-names>G</given-names></name><name><surname>Duah</surname><given-names>KB</given-names></name><name><surname>Andrews</surname><given-names>LE</given-names></name><name><surname>Shi</surname><given-names>WQ</given-names></name><name><surname>High</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An alternative pathway for membrane protein biogenesis at the endoplasmic reticulum</article-title><source>Commun Biol</source><volume>4</volume><elocation-id>828</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-02363-z</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Keefe</surname><given-names>S</given-names></name><name><surname>Pool</surname><given-names>MR</given-names></name><name><surname>High</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Membrane protein biogenesis at the ER: the highways and byways</article-title><source>The FEBS Journal</source><volume>289</volume><fpage>6835</fpage><lpage>6862</lpage><pub-id pub-id-type="doi">10.1111/febs.15905</pub-id><pub-id pub-id-type="pmid">33960686</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>RT</given-names></name><name><surname>Wagner</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Metabolism and turnover of cell surface-associated heparan sulfate proteoglycan and chondroitin sulfate proteoglycan in normal and cholesterol-enriched macrophages</article-title><source>Arteriosclerosis and Thrombosis</source><volume>11</volume><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1161/01.atv.11.6.1752</pub-id><pub-id pub-id-type="pmid">1931877</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>E</given-names></name><name><surname>Schülein</surname><given-names>R</given-names></name><name><surname>Vermeire</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhibitors of the Sec61 complex and novel high throughput screening strategies to target the protein translocation pathway</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>12007</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222112007</pub-id><pub-id pub-id-type="pmid">34769437</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Bandla</surname><given-names>C</given-names></name><name><surname>García-Seisdedos</surname><given-names>D</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>Kamatchinathan</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Frericks-Zipper</surname><given-names>A</given-names></name><name><surname>Eisenacher</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id><pub-id pub-id-type="pmid">34723319</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puerta-Guardo</surname><given-names>H</given-names></name><name><surname>Glasner</surname><given-names>DR</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dengue Virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005738</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005738</pub-id><pub-id pub-id-type="pmid">27416066</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitsma</surname><given-names>S</given-names></name><name><surname>Slaaf</surname><given-names>DW</given-names></name><name><surname>Vink</surname><given-names>H</given-names></name><name><surname>van Zandvoort</surname><given-names>MAMJ</given-names></name><name><surname>oude Egbrink</surname><given-names>MGA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The endothelial glycocalyx: composition, functions, and visualization</article-title><source>Pflugers Archiv</source><volume>454</volume><fpage>345</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/s00424-007-0212-8</pub-id><pub-id pub-id-type="pmid">17256154</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarfo</surname><given-names>FS</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Wansbrough-Jones</surname><given-names>M</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease</article-title><source>Cellular Microbiology</source><volume>18</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1111/cmi.12547</pub-id><pub-id pub-id-type="pmid">26572803</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schorr</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Haßdenteufel</surname><given-names>S</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Cavalié</surname><given-names>A</given-names></name><name><surname>Greiner</surname><given-names>M</given-names></name><name><surname>Weissgerber</surname><given-names>P</given-names></name><name><surname>Loi</surname><given-names>M</given-names></name><name><surname>Paton</surname><given-names>AW</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name><name><surname>Molinari</surname><given-names>M</given-names></name><name><surname>Förster</surname><given-names>F</given-names></name><name><surname>Dudek</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Helms</surname><given-names>V</given-names></name><name><surname>Zimmermann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of signal peptide features for substrate specificity in human Sec62/Sec63-dependent ER protein import</article-title><source>The FEBS Journal</source><volume>287</volume><fpage>4612</fpage><lpage>4640</lpage><pub-id pub-id-type="doi">10.1111/febs.15274</pub-id><pub-id pub-id-type="pmid">32133789</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>RE</given-names></name><name><surname>Lali</surname><given-names>FV</given-names></name><name><surname>Smallie</surname><given-names>T</given-names></name><name><surname>Small</surname><given-names>PLC</given-names></name><name><surname>Foxwell</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism</article-title><source>Journal of Immunology</source><volume>182</volume><fpage>2194</fpage><lpage>2202</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0802294</pub-id><pub-id pub-id-type="pmid">19201873</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sixt</surname><given-names>M</given-names></name><name><surname>Engelhardt</surname><given-names>B</given-names></name><name><surname>Pausch</surname><given-names>F</given-names></name><name><surname>Hallmann</surname><given-names>R</given-names></name><name><surname>Wendler</surname><given-names>O</given-names></name><name><surname>Sorokin</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis</article-title><source>The Journal of Cell Biology</source><volume>153</volume><fpage>933</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1083/jcb.153.5.933</pub-id><pub-id pub-id-type="pmid">11381080</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalinskaitė</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Lewis</surname><given-names>AJO</given-names></name><name><surname>Keenan</surname><given-names>RJ</given-names></name><name><surname>Hegde</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanism of an intramembrane chaperone for multipass membrane proteins</article-title><source>Nature</source><volume>611</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05336-2</pub-id><pub-id pub-id-type="pmid">36261528</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Fidanze</surname><given-names>S</given-names></name><name><surname>Benowitz</surname><given-names>AB</given-names></name><name><surname>Kishi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Total synthesis of the mycolactones</article-title><source>Organic Letters</source><volume>4</volume><fpage>647</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1021/ol0172828</pub-id><pub-id pub-id-type="pmid">11843613</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Buscher</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Di Russo</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lütke-Enking</surname><given-names>S</given-names></name><name><surname>Zarbock</surname><given-names>A</given-names></name><name><surname>Stadtmann</surname><given-names>A</given-names></name><name><surname>Striewski</surname><given-names>P</given-names></name><name><surname>Wirth</surname><given-names>B</given-names></name><name><surname>Kuzmanov</surname><given-names>I</given-names></name><name><surname>Wiendl</surname><given-names>H</given-names></name><name><surname>Schulte</surname><given-names>D</given-names></name><name><surname>Vestweber</surname><given-names>D</given-names></name><name><surname>Sorokin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial basement membrane laminin 511 contributes to endothelial junctional tightness and thereby inhibits leukocyte transmigration</article-title><source>Cell Reports</source><volume>18</volume><fpage>1256</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.092</pub-id><pub-id pub-id-type="pmid">28147279</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spenlé</surname><given-names>C</given-names></name><name><surname>Simon-Assmann</surname><given-names>P</given-names></name><name><surname>Orend</surname><given-names>G</given-names></name><name><surname>Miner</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Laminin α5 guides tissue patterning and organogenesis</article-title><source>Cell Adhesion &amp; Migration</source><volume>7</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.4161/cam.22236</pub-id><pub-id pub-id-type="pmid">23076210</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaram</surname><given-names>A</given-names></name><name><surname>Yamsek</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Hooda</surname><given-names>Y</given-names></name><name><surname>Hegde</surname><given-names>RS</given-names></name><name><surname>Keenan</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Substrate-driven assembly of a translocon for multipass membrane proteins</article-title><source>Nature</source><volume>611</volume><fpage>167</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05330-8</pub-id><pub-id pub-id-type="pmid">36261522</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Vlodavsky</surname><given-names>I</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Helicobacter pylori-induced heparanase promotes <italic>H. pylori</italic> colonization and gastritis</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>675747</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.675747</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thyboll</surname><given-names>J</given-names></name><name><surname>Kortesmaa</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Soininen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Iivanainen</surname><given-names>A</given-names></name><name><surname>Sorokin</surname><given-names>L</given-names></name><name><surname>Risling</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Tryggvason</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Deletion of the laminin alpha4 chain leads to impaired microvessel maturation</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>1194</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.4.1194-1202.2002</pub-id><pub-id pub-id-type="pmid">11809810</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voorhees</surname><given-names>RM</given-names></name><name><surname>Hegde</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of the Sec61 channel opened by a signal sequence</article-title><source>Science</source><volume>351</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1126/science.aad4992</pub-id><pub-id pub-id-type="pmid">26721998</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallez</surname><given-names>Y</given-names></name><name><surname>Huber</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis</article-title><source>Biochimica et Biophysica Acta</source><volume>1778</volume><fpage>794</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.09.003</pub-id><pub-id pub-id-type="pmid">17961505</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warboys</surname><given-names>CM</given-names></name><name><surname>Ghim</surname><given-names>M</given-names></name><name><surname>Weinberg</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Understanding mechanobiology in cultured endothelium: A review of the orbital shaker method</article-title><source>Atherosclerosis</source><volume>285</volume><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2019.04.210</pub-id><pub-id pub-id-type="pmid">31096159</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagishita</surname><given-names>M</given-names></name><name><surname>Hascall</surname><given-names>VC</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Proteoglycans synthesized by rat ovarian granulosa cells in culture: isolation, fractionation, and characterization of proteoglycans associated with the cell layer</article-title><source>The Journal of Biological Chemistry</source><volume>259</volume><fpage>10260</fpage><lpage>10269</lpage><pub-id pub-id-type="pmid">6469964</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>O</given-names></name><name><surname>Afsar</surname><given-names>B</given-names></name><name><surname>Ortiz</surname><given-names>A</given-names></name><name><surname>Kanbay</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of endothelial glycocalyx in health and disease</article-title><source>Clinical Kidney Journal</source><volume>12</volume><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfz042</pub-id><pub-id pub-id-type="pmid">31583086</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yotsu</surname><given-names>RR</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Simmonds</surname><given-names>RE</given-names></name><name><surname>Bedimo</surname><given-names>R</given-names></name><name><surname>Ablordey</surname><given-names>A</given-names></name><name><surname>Yeboah-Manu</surname><given-names>D</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Asiedu</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Buruli Ulcer: a review of the current knowledge</article-title><source>Current Tropical Medicine Reports</source><volume>5</volume><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1007/s40475-018-0166-2</pub-id><pub-id pub-id-type="pmid">30460172</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousif</surname><given-names>LF</given-names></name><name><surname>Di Russo</surname><given-names>J</given-names></name><name><surname>Sorokin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Laminin isoforms in endothelial and perivascular basement membranes</article-title><source>Cell Adhesion &amp; Migration</source><volume>7</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.4161/cam.22680</pub-id><pub-id pub-id-type="pmid">23263631</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Ebong</surname><given-names>EE</given-names></name><name><surname>Fu</surname><given-names>BM</given-names></name><name><surname>Tarbell</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The structural stability of the endothelial glycocalyx after enzymatic removal of glycosaminoglycans</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e43168</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0043168</pub-id><pub-id pub-id-type="pmid">22905223</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Cankova</surname><given-names>Z</given-names></name><name><surname>Iwanaszko</surname><given-names>M</given-names></name><name><surname>Lichtor</surname><given-names>S</given-names></name><name><surname>Mrksich</surname><given-names>M</given-names></name><name><surname>Ameer</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Potent laminin-inspired antioxidant regenerative dressing accelerates wound healing in diabetes</article-title><source>PNAS</source><volume>115</volume><fpage>6816</fpage><lpage>6821</lpage><pub-id pub-id-type="doi">10.1073/pnas.1804262115</pub-id><pub-id pub-id-type="pmid">29891655</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>G</given-names></name><name><surname>Barber</surname><given-names>E</given-names></name><name><surname>Aljewari</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>WQ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Total synthesis and biological evaluation of ipomoeassin F and its unnatural 11R-Epimer</article-title><source>The Journal of Organic Chemistry</source><volume>80</volume><fpage>9279</fpage><lpage>9291</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.5b01765</pub-id><pub-id pub-id-type="pmid">26317990</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>O’Keefe</surname><given-names>S</given-names></name><name><surname>Tranter</surname><given-names>D</given-names></name><name><surname>Iannotti</surname><given-names>MJ</given-names></name><name><surname>Baron</surname><given-names>L</given-names></name><name><surname>Hall</surname><given-names>B</given-names></name><name><surname>Corfield</surname><given-names>K</given-names></name><name><surname>Paatero</surname><given-names>AO</given-names></name><name><surname>Henderson</surname><given-names>MJ</given-names></name><name><surname>Roboti</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Govindarajan</surname><given-names>M</given-names></name><name><surname>Rohde</surname><given-names>JM</given-names></name><name><surname>Blanchard</surname><given-names>N</given-names></name><name><surname>Simmonds</surname><given-names>R</given-names></name><name><surname>Inglese</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name><name><surname>High</surname><given-names>S</given-names></name><name><surname>Paavilainen</surname><given-names>VO</given-names></name><name><surname>Shi</surname><given-names>WQ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ipomoeassin F Binds Sec61α to inhibit protein translocation</article-title><source>Journal of the American Chemical Society</source><volume>141</volume><fpage>8450</fpage><lpage>8461</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b13506</pub-id><pub-id pub-id-type="pmid">31059257</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Duah</surname><given-names>KB</given-names></name><name><surname>Andrews</surname><given-names>LE</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>O’Keefe</surname><given-names>S</given-names></name><name><surname>Whisenhunt</surname><given-names>L</given-names></name><name><surname>Shim</surname><given-names>JS</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>High</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>WQ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ring expansion leads to a more potent analogue of ipomoeassin F</article-title><source>The Journal of Organic Chemistry</source><volume>85</volume><fpage>16226</fpage><lpage>16235</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.0c01659</pub-id><pub-id pub-id-type="pmid">33264019</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86931.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Henrion</surname><given-names>Daniel</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Angers</institution><country>France</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>The toxin mycolactone is produced by Mycobacterium ulcerans which is responsible for the Buruli ulcer lesions. The authors performed a <bold>valuable</bold> study showing the effects of mycolactone on blood vessel integrity. This <bold>convincing</bold> data provides new therapeutic targets to accelerate the healing of Buruli ulcer lesions.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86931.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>By employing human primary microvascular endothelial cells, along with live confocal imaging, proteomics, and chemical validation studies, the authors reveal a novel cellular mechanism underlying mycolactone's effects in Buruli ulcer lesions. This finding provides important insights into the specific mechanisms of skin pathogenesis.</p><p>Strengths:</p><p>The techniques employed are state-of-the-art.</p><p>Weaknesses:</p><p>The study lacks genetic validation of the findings.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86931.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The authors have investigated the effect of the toxin mycolactone produced by Mycobacterium ulcerans on the endothelium. Mycobacterium ulcerans is involved in Buruli ulcer lesions classified as a neglected disease by WHO. This disease has dramatic consequences on the microcirculation causing important cutaneous lesions. The authors have previously demonstrated that endothelial cells are especially sensitive to mycolactone. The present study brings more insight into the mechanism involved in mycolactone-induced endothelial cells defect and thus in microcirculatory dysfunction. The authors showed that mycolactone directly affected the synthesis of proteoglycans at the level of the golgi with a major consequence on the quality of the glycocalyx and thus on the endothelial function and structure. Importantly, the authors show that blockade of the enzyme involve in this synthesis (galactosyltransferase II) phenocopied the effects of mycolactone. The effect of mycolactone on the endothelium was confirmed in vivo. Finally, the authors showed that exogenous laminin-511 reversed the effects of mycolactone, thus opening an important therapeutic perspective for the treatment of wound healing in patients suffering Buruli ulcer lesions.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86931.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hsieh</surname><given-names>Louise Tzung-Harn</given-names></name><role specific-use="author">Author</role><aff><institution>University of Surrey</institution><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Belinda S</given-names></name><role specific-use="author">Author</role><aff><institution>University of Surrey</institution><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Newcombe</surname><given-names>Jane</given-names></name><role specific-use="author">Author</role><aff><institution>University of Surrey</institution><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Mendum</surname><given-names>Tom A</given-names></name><role specific-use="author">Author</role><aff><institution>University of Surrey</institution><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Varela</surname><given-names>Sonia Santana</given-names></name><role specific-use="author">Author</role><aff><institution>University of Surrey</institution><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Umrania</surname><given-names>Yagnesh</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Deery</surname><given-names>Michael J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Wei Q</given-names></name><role specific-use="author">Author</role><aff><institution>Ball State University</institution><addr-line><named-content content-type="city">Muncie</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Diaz-Delgado</surname><given-names>Josué</given-names></name><role specific-use="author">Author</role><aff><institution>Texas A&amp;M University</institution><addr-line><named-content content-type="city">College Station</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Salguero</surname><given-names>Francisco J</given-names></name><role specific-use="author">Author</role><aff><institution>United Kingdom Health Security Agency</institution><addr-line><named-content content-type="city">Salisbury</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Simmonds</surname><given-names>Rachel E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Surrey</institution><addr-line><named-content content-type="city">Guildford</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the current reviews.</p><p><bold>Response to reviewer 1:</bold></p><p>We thank the reviewer for their positive comments and note that we made many attempts to genetically alter endothelial cells to expression mutants of SEC61A1 that are resistant to the effects of mycolactone. However, these cells were not capable of supporting expression of this transgene. Instead, we used an approach where we tested other translocation inhibitors, with a different chemical structure but same mechanism of action at the Sec61 translocon and found that these phenocopied the effects.</p><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>The authors have investigated the effect of the toxin mycolactone produced by mycobacterium ulcerans on the endothelium. Mycobacterium ulcerans is involved in Buruli ulcer classified as a neglected disease by WHO. This disease has dramatic consequences on the microcirculation causing important cutaneous lesions. The authors have previously demonstrated that endothelial cells are especially sensitive to mycolactone. The present study brings more insight into the mechanism involved in mycolactone-induced endothelial cells defect and thus in microcirculatory dysfunction. The authors showed that mycolactone directly affected the synthesis of proteoglycans at the level of the golgi with a major consequence on the quality of the glycocalyx and thus on the endothelial function and structure. Importantly, the authors show that blockade of the enzyme involve in this synthesis (galactosyltransferase II) phenocopied the effects of mycolactone. The effect of mycolactone on the endothelium was confirmed in vivo. Finally, the authors showed that exogenous laminin-511 reversed the effects of mycolactone, thus opening an important therapeutic perspective for the treatment of wound healing in patients suffering Buruli ulcer and presenting lesions.</p><p><bold>Reviewer #2 (Public Review):</bold></p><p>The authors dissected the effects of mycolacton on endothelial cell biology and vessel integrity. The study follows up on previous work by the same group, which highlighted alterations in vascular permeability and coagulation in patients with Buruli ulcer. It provides a mechanistic explanation for these clinical observations, and suggests that blockade of Sec61 in endothelial cells contributes to tissue necrosis and slow wound healing.</p><p>Overall, the generated data support their conclusions and I only have two major criticisms:</p><p>- Replicating the effects of mycolactone on endothelial parameters with Ipomoeassin F (or its derivative ZIF-80) does not demonstrate that these effects are due to Sec61 blockade. This would require genetic proof, using for example endothelial cells expressing Sec61A mutants that confer resistance to mycolactone blockade. The authors claimed in the Discussion that they could not express such mutants in primary endothelial cells, but did they try expressing mutants in HUVEC cell lines? Without such genetic evidence all statements claiming a causative link between the observed effects on endothelial parameters and Sec61 blockade should be removed or rephrased. The same applies to speculations on the role of Sec61 in epithelial migration defects in discussion. Data corresponding to Ipomoeassin F and ZIF-80 do not add important information, and may be removed or shown as supplemental information.</p><p>- While statistical analysis is done and P values are provided, no information is given on the statistical tests used, neither in methods nor results. This must be corrected, to evaluate the repeatability and reproducibility of their data.</p></disp-quote><p>We respectfully but fundamentally disagree with the comments regarding the Sec61 dependence of the effects that we observed. We showed that loss of glycocalyx and basement membrane components underpinned the phenotypic changes in endothelial cells (morphological changes, loss of adhesion, increased permeability, and reduced ability to repair scratch wounds). We demonstrated that we could phenocopy permeability increases and elongation phenotype by knocking down the type II membrane protein B3Galt6, and reverse the adhesion defect by exogenous provision of the secreted laminin-511 heterotrimer.</p><p>Our conclusion that mycolactone mediates these effects via Sec61 inhibition is not based solely on the use of alternative inhibitors but is built on several pillars of evidence:</p><p>First, the proteomics data conforms entirely to predictions based on the topology of affected vs. non-effected proteins, and agrees with independently published proteomic datasets from T lymphocytes, dendritic cells and sensory neurons (ref.12), as well as biochemical studies performed using in vitro translocation assays (ref.11,34). Furthermore, the pattern of membrane protein down regulation observed in our experiments fits perfectly with established models of protein translocation mechanisms, particularly with respect to the lack of effect on specific topologies of multipass membrane proteins, tail anchored- and type III membrane proteins (ref.34-36).</p><p>Second, since Sec61 very highly conserved amongst mammals and is found in all nucleated cells, it is hard to conceptualise a framework in which mycolactone targets Sec61 in some cells and not others, as this reviewer suggests might be the case for epithelial cells [noting that the work being referred to (ref.29) predates our 2014 work showing that mycolactone is a Sec61 inhibitor (ref.7)]. Indeed, mycolactone has been shown to target Sec61 in multiple independent approaches including forward genetic screens involving random mutagenesis and CRISPR/Cas9 (ref.10, PMID: 35939511). Genetic evidence has previously been provided for the Sec61 dependence of mycolactone effects in epithelial cells (ref.10,17). We have unpublished genetic evidence that the rounding and detachment of epithelial cells due to mycolactone is reduced when resistance mutations are over expressed, and will consider including this in the next version of the manuscript.</p><p>Third, given this weight of evidence, one would be hard-pressed to provide an alternative explanation for the specific down-regulation of glycosaminoglycan-synthesising enzymes and adhesion/basement membrane molecules while most cytosolic and non-Sec61 dependent membrane proteins are unchanged or upregulated. However, seeking to be as rigorous as possible we have here shown that a completely independent Sec61 inhibitor produces the same phenotype at the gross and molecular level. Ipomoeassin F (Ipom-F) is a glycolipid, not a polyketide lactone, yet they both compete for binding with cotransin in Sec61α (ref.6). There is significant overlap in the cellular responses to mycolactone and Ipom-F, including the induction of the integrated stress response (ref.17, PMID: 34079010), which we observed again in the current data, providing further evidence that this approach is useful when genetic approaches are technically unattainable.</p><p>Therefore, we are confident the effects seen on endothelial cells are Sec61-dependent. We are happy to provide more detail on our lengthy attempts at over-expressing mycolactone resistant SEC61A1 genes in HUVECs; primary endothelial cells derived from the umbilical vein. We are highly experienced in this area, and have previously stably expressed these proteins in epithelial cell lines, reproducing the resistance profile (ref.10,17). Notably though, these cells do not have normal ‘fitness’ in the absence of challenge. Since endothelial cells (and endothelial cell lines; PMID: 12560236) are extremely hard to transfect with plasmids, with efficiency routinely 5-10% (including in our hands), we developed a lentivirus system. We were eventually (after multiple attempts using different protocols) able to transduce primary HUVECs with constructs expressing GFP (at an efficiency of about 10-20%) and select/expand these under puromycin selection. Never-the-less, we never recovered any cells that expressed the flag-tagged SEC61A1 wild type or SEC61A1 carrying the resistance mutant D60G. We also attempted to select D60G-transduced cells with mycolactone epimers, an approach that can help the cells compete against non-transduced cells in culture flasks (ref.10). We concluded that primary endothelial cells are unable to tolerate the expression of additional Sec61α, and this was incompatible with survival.</p><p>It’s also important to note that most endothelial cell specialists would agree that endothelial cell lines are not good models of endothelial behaviour. We tested the HMEC-1 cell line, but found it did not express prototypical endothelial marker vWF in the expected way. Therefore we focussed our efforts on primary endothelial cells. Should we be able to overcome the dual challenge of the necessity to work in primary cells, and the difficulty of over-expressing Sec61, we will update this paper at a later date with this data, and will also expand the above arguments.</p><p>We apologise for the embarrassing oversight of not including information about the statistical analyses we used, which of course we will correct in full in the revised version. However, we would like to provide this information to readers of the current version of the manuscript. All data were analysed using GraphPad Prism Version 9.4.1:</p><p>Figure 1: one-way ANOVA with Dunnett’s (panel A) or Tukey’s (panel B) correction for multiple comparisons</p><p>Figure 2 supplement: one-way ANOVA with Tukey’s correction for multiple comparisons (analysed panel)</p><p>Figure 3: one-way ANOVA with Tukey’s (panel B) or Dunnett’s (panel E&amp;F) correction for multiple comparisons</p><p>Figure 4: one-way ANOVA with Dunnett’s correction for multiple comparisons (all analysed panels)</p><p>Figure 5 and supplement: one-way ANOVA with Dunnett’s correction for multiple comparisons (all analysed panels)</p><p>Figure 6: one-way ANOVA with Dunnett’s correction for multiple comparisons (analysed panel)</p><p>Figure 6 supplement: one-way ANOVA with Dunnett’s correction for multiple comparisons (all analysed panels)</p><p>Figure 7: two-way ANOVA with Tukey’s correction for multiple comparisons (all analysed panels; panels B&amp;C also included the Geisser Greenhouse correction for sphericity)</p><p>Figure 7 supplement: Panels A&amp;D used a repeated measures one-way ANOVA with Dunnett’s correction for multiple comparisons (panel D also included the Geisser Greenhouse correction for sphericity). Panels B,C&amp;E used a two-way ANOVA with Tukey’s correction for multiple comparisons (panels B&amp;C also included the Geisser Greenhouse correction for sphericity)</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Buruli ulcer is a severe skin infection in humans that is caused by a bacterium, Mycobacterium ulcerans. The main clinical sign is a massive tissue necrosis subsequent to an edema stage. The main virulence factor called mycolactone is a polyketide with a lactone core and a long alkyl chain that is released within vesicles by the bacterium. Mycolactone was already shown to account for several disease phenotypes characteristic of Buruli ulcer, for instance tissue necrosis, host immune response modulation and local analgesia. A large number of cellular pathways in various cell types was reported to be impacted by mycolactone. Among those, the Sec61 translocon involved in the transport of certain proteins to the endoplasmic reticulum was first identified by the authors of the study and is currently the most consensual target. Mycolactone disruption of Sec61 function was then shown to directly impact on cell apoptosis in macrophages, limited immune responses by T-cells and increased autophagy in dermal endothelial cells and fibroblasts. In their manuscript, TzungHarn Hsieh and their collaborators investigated the Sec61- dependent role of mycolactone on morphology, adhesion and migration of primary human dermal microvascular endothelial cells (HDMEC). They used a combination of sugar and proteomic studies on a live imagebased phenotypic assay on HDMEC to characterize the effect of mycolactone. First, they showed that upon incubation of monolayer of HDMEC with mycolactone at low dose (10 ng/mL) for 24h, the cells become elongated before rounding and eventually detached from the culture dish at 48h. Next, mycolactone was probed on a scratch assay and migration of the cells ceased upon a 24h incubation. The same effect as mycolactone on these two assays was observed for two other Sec61 inhibitors Ipomoeassin F and ZIF-80. Then, the authors resorted to the widely established mouse footpad model of M. ulcerans infection to evidence fibrinogen accumulation outside the blood vessel within the endothelium at 28 days postinfection, correlating with severe endothelial cell morphology changes.</p><p>To dissect the molecular pathways involved in these phenotypes, the authors performed an HDMEC membrane protein analysis and showed a decrease in the numbers of proteins involved in glycosylation and adhesion. As protein glycosylation mainly occurs in the Golgi apparatus, a deeper analysis revealed that enzymes involved in glycosaminoglycan (GAG) synthesis were lost in mycolactone treated HDMEC. A combination of immunofluorescence and flow cytometry approaches confirmed the impact of mycolactone on the ability of endothelial cells to synthesize GAG chains. The mycolactone effect on cell elongation was phenocopied by knock-down of galactosyltransferase II (B3Galt6) involved in GAG biosynthesis. A second extensive analysis of the endothelial basement membrane component and their ligands identified multiple laminins affected by mycolactone. Using similar functional studies as for GAG, the impact of mycolactone on cell rounding and migration could be reversed by the addition of laminin α5.</p><p>The major strengths of the study relies on a combination of cleverly designed phenotypic assays and in-depth cleverly designed membrane proteomic studies and follow-up analysis.</p><p>The results really support the conclusions. Congratulations!</p><p>The discussion takes into account the current state of the art, which has mostly been established by the authors of the present manuscript.</p><p><bold>Recommendations for the authors:</bold></p></disp-quote><p>In preparing this revised version we have made a number of general improvements:</p><p>• We added the missing information on statistical analysis that was mentioned in the public review of reviewer #2</p><p>• We have changed all gene names to the HUGO nomenclature</p><p>• We have changed our abbreviation of mycolactone from “MYC” to “Myco” in all figures to avoid any potential confusion with other protein factors</p><p>• We have moved the fibrin(ogen) staining of the mouse footpads to its own figure (now Fig 2), partly due to the inclusion of additional data in Fig 1. This has changed the numbering of subsequent figures, but has also made the supplementary figures easier to track.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>(1) Figure 1I. When mice are injected M. Ulcerens a measurement of local blood flow would be very informative in addition of the data shown. Cutaneous blood flow at the level of the feet is possible using laser doppler or Laser speckle imaging. With these measurements the authors would have a functional quantification of the effect of the glycosaminoglycans- Sec61α associated damages on the microcirculatory blood flow. The same measurement could also better validate the therapeutic effect of laminin.</p></disp-quote><p>We thank the reviewer for this great suggestion, and respectfully remind the reviewer that these experiments take place in CL3 containment. This often completely precludes certain procedures due to the availability of equipment inside the containment, and our ability to sterilise it. Where we are able to perform procedures, it greatly increases their complexity since any procedures on live animals must take place inside of a cabinet. Therefore, we can only use equipment that we have at our animal facility. It is not trivial to set up the regulatory permissions to perform these experiments at other facilities where more specialist equipment is located due to the containment restrictions.</p><p>Never-the-less we have attempted to perform ultrasound imaging of mouse feet using the VivoF and have set up a collaboration with other researchers at Surrey who have developed a novel imaging instrument to measure microvascular circulation call optical coherence tomography (OCT; <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34882760/">https://pubmed.ncbi.nlm.nih.gov/34882760/</ext-link><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34882760/">)</ext-link>, and we are working with them to develop a protocol that be used in small rodents.</p><p>However, while we have dedicated considerable time to trying to perform the suggested experiment, we have not been successful within a reasonable time frame. Consequently, if we are able to establish this technique in the <italic>M. ulcerans</italic> infection model, and/or OCT in small rodents, this will likely be beyond the scope of the current manuscript and will be a publication in its own right. We note that we have been able to perform almost all of the other requested experiments (see below), and have also been able to undertake transmission electron microscopy of <italic>M. ulcerans</italic> infected mouse footpads, which confirms the loss of the basement membrane at high resolution (Fig 7E).</p><disp-quote content-type="editor-comment"><p>(2) Figure 1 -D. Endothelial cells were exposed to mycolactone, Ipomoeassin F or ZIF-80. The effect on the cells is clear and impressive. Nevertheless, endothelial cells in no flow conditions are considered &quot;diseased&quot; cells as in the areas of low flow or no flow are prone to atherosclerosis in vivo. Would the authors expect similar effects in cells submitted to flow? In this conditions cells would be already elongated in the direction of flow.</p></disp-quote><p>We agree that flow is usually experienced by endothelial cells <italic>in vivo</italic>, and have repeated a selection of our experiments under conditions that mimic flow and produce uniaxial shear stress. All showed a similar pattern of response to mycolactone, including the phenotypic changes (Fig 1I-K), loss of perlecan (Fig S6C) and laminin α4 (Fig S7B). It is true that the elongation phenotype is not as striking in a cell monolayer that already contains many elongated cells, but qualitatively the cells become disorganised and at 48 hours, their length/width ratio had increase. These results provide reassurance that our findings are physiologically relevant.</p><disp-quote content-type="editor-comment"><p>(3) Discuss the possible consequences of your findings on vascular reactivity and especially on flow-mediated dilation and/or flow-mediated remodeling which as both are important in tissue repair and wound healing.</p></disp-quote><p>We agree with this reviewer that there are likely to be broad consequences to endothelial and vascular function as a result of our findings here. Vascular reactivity is not something we directly considered in this manuscript, and is probably better linked to our planned future work, laid out above, regarding vascular flow in the infected animals. While a key mediator of vascular tone, endothelin 1, is a Sec61-dependent secreted peptide mediator (and is likely to also be affected by mycolactone’s actions), this was not one of the &gt;6500 proteins we identified in our proteomic study. On the other hand, it has been shown by others that mycolactone can induce NO production by in other types of cells.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>- The authors use a mouse model of M. ulcerans infection of footpads to assess the in vivo relevance of their results. It would be useful to comment on any differences between human and mouse with regard to endothelial cell biology and vessel wall architecture. Since the authors have access to patients samples, parallel stainings in human lesions would have strengthened the study.</p></disp-quote><p>This is an important issue, and is one we have already addressed in our two previous articles <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35100311/">https://pubmed.ncbi.nlm.nih.gov/35100311/</ext-link> <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/26181660/">https://pubmed.ncbi.nlm.nih.gov/26181660/</ext-link> . Indeed, this latter work already included a detailed analysis of fibrin staining in these Buruli ulcer patient biopsies and underpinned the hypothesis that we have now tested in the current manuscript.</p><p>It is worth noting that our data supports that the critical step is at an early (pre-clinical) stage, for which patient samples are not available. The proposed human challenge model <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/37384606/">(</ext-link><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/37384606/">https://pubmed.ncbi.nlm.nih.gov/37384606/</ext-link>) may well provide a suitable platform such studies in the future.</p><disp-quote content-type="editor-comment"><p>- The authors should provide in the Discussion some explanation for the differential effects of Laminin-11, -411 and -511 in Fig. 7</p></disp-quote><p>This is an interesting point, and probably related to the expression of laminin binding proteins by mycolactone-exposed endothelial cells. We pursued several candidates based on the proteomic data but could not identify a unique gene that explained this observation. Mostly likely they are explained by partial (be it low or high) loss of a combination of integrin binding proteins. Since this was rather inconclusive and we preferred not to present this data, and already said (p34-35) “We have not been able to ascribe this to the retention of a specific adhesion molecule, and instead postulate that rescue could be via residual expression of a wide variety of laminin α5 receptors.”</p><disp-quote content-type="editor-comment"><p>- The word &quot;catastrophic&quot; in the title is very dramatic given the limited impact on the vital prognosis of patients</p></disp-quote><p>This word has been changed to “destructive”</p><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>Several points could be further discussed:</p><p>-In mouse model of M. ulcerans infection, in 5% of cases, animals heal spontaneously. How could the authors results contribute to bring hypothesis to this phenomenon?</p><p>Others have shown that the ability of some mice to control <italic>M. ulcerans</italic> infection is related to loss of mycolactone production by an unknown mechanism. It is not something we have ever observed in the infection experiments we have performed, although this may be due to the humane endpoints of our licence. However, this seems somewhat outside the main focus of the paper and we have not discussed this further.</p><p>-Mycolactone was also reported to induce analgesia in the mouse model. There is still controversy about the precise mechanisms involved in this mycolactone mediated painless effect. Could the data obtained here help to resolve the controversy?</p><p>We agree that analgaesia in <italic>M. ulcerans</italic> infection (both in mouse models and in clinical infections) is an extremely interesting area. However, we cannot mechanistically link loss of vascular integrity with the analgaesia based on the data generated in the current manuscript. Therefore we prefer not to speculate on this.</p><p>The quantification of the microscopy images and videos should be provided as well as the script used to quantify them.</p><p>The reviewer is not specific about which microscopy images are being referred to in this comment, but the reference to videos leads us to assume this is related to the ZenCell OWL images/videos presented in Figure 1 and Figure S1. We had already provided quantification of these in the graphs provided, and the algorithms use for % coverage and % detached cells were provided in the instrument software used to gather the data, the ZenCell OWL (which are proprietary). Other counts were made manually, and the length:width ratio is simple arithmetic as already described in the methodology.</p><p>The authors performed their work using chemically synthesized mycolactone obtained from the very generous Professor Kishi (Harvard University). Would the same phenotype and proteomics analysis be obtained with biologically purified mycolactone?</p><p>Our lab has extensive experience of both biologically purified and synthetic mycolactone, and the phenotypes observed have always been identical when using the chemically synthesised form. Therefore we did not repeat the proteomics experiments as we do not believe it would provide any greater insight into the disease mechanism. However, we have now replicated a range of findings using mycolactone biologically purified from <italic>M. ulcerans</italic>. In particular, we confirmed that the cytotoxic activity of synthetic and biological mycolactone are inseparable (Figure S1A), and the main phenotypic changes induced by mycolactone in endothelial cells (Phenotypes; Figures S1D-F, B3GALT6/perlecan/laminin α5 loss; S5A, S6B, S7A).</p><p>Although already very comprehensive, a kinetic study of their proteomic analysis over time could strengthen the analysis (from 2H to 48H).</p><p>We agree that more data is always better, but since we validated our proteomic data set over multiple timepoints between 2 and 48 hrs, we do not believe this would alter the main conclusions of our work.</p><p>The siRNA transfection protocol could be better described. A Table listing all the reagents would help the reader.</p><p>A more detailed siRNA transfection protocol has been added to the methods section, and we now include a Key Resources Table at the start of the Materials &amp; Methods section.</p></body></sub-article></article>